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1 Introduction and Objectives of the Thesis 
1.1 Introduction 
1.1.1 Bone Tissue Engineering 
Bone is a living tissue, undergoing constant remodeling and self-renewal comprising 
the ability to repair itself [Hing, 2004; Phillips, 2005]. Due to this fact, restorative 
surgical intervention, e.g. after fractures, usually requires not more than alignment 
and stable fixation. However, if self-repair mechanisms are overstrained, in case of 
non-unions or critical size defects, bone grafting is necessary [Shepherd and Best, 
2011]. In clinical use nowadays, the gold standard for bone regeneration still is the 
use of autologous bone grafting material [Dimitriou et al., 2011; Quarto et al., 2001]. 
However, harvesting surgery to obtain the graft material comprises the risk of 
infections or donor-site morbidity [Kurz et al., 1989; Seiler and Johnson, 2000]. The 
use of allograft material (e.g. demineralized bone matrix) can lead to immunologic 
reactions [Benichou, 1999; Stevenson, 1987], the transmission of diseases [Moucha 
et al., 2007], and increases the risk of infections [Lord et al., 1988].  
A disease associated with increased fracture rates is osteoporosis [Johnell et al., 
2004; Kanis, 1994]. A quarter of the Germans older than 50 years is currently 
suffering from osteoporosis [Häussler et al., 2006] and one out of three women and 
one out of five men over 50 years will suffer from a fracture caused by osteoporosis 
[Pollähne et al., 2007]. By the year 2030, about half of the German population will be 
50 years or older [Statistisches Bundesamt, 2009].  
With this in mind, there is an increasing demand for orthopedic implants (for 
replacement of diseased tissue and for non-union defects) integrating in recipient’s 
body tissue and for fillers to treat critical size defects [Rose and Oreffo, 2002]. Tissue 
engineering is a considerable option as this interdisciplinary field aims on the 
development of adequate replacements for non-functional tissue to maintain, restore, 
or improve its function [Langer and Vacanti, 1993]. Currently bone tissue engineering 
is most frequently used in, but not limited to, dental applications, due to the relatively 
small defect sites needing reconstructive approaches [Ueda, 2011].  
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The generation of new tissue can be performed by in vitro expansion of harvested 
cells in a bioreactor and seeding on a 3-D scaffold (Figure 1-1). Alternatively the 
recipient body can be used as a bioreactor itself, when a freshly cell-seeded scaffold, 
or an unseeded scaffold is implanted into the defect site and cells are injected after a 
certain period or surrounding cells infiltrate the scaffold [Rose and Oreffo, 2002].  
 
 
Figure 1-1: Typical strategy for tissue engineering, adapted from [Rose and Oreffo, 
2002]. 
 
For successful bone regeneration, three key factors are required and will be further 
reviewed within the following sections: osteogenic cells, an osteoconductive scaffold, 
and osteoinductive growth factors [Giannoudis et al., 2005]. Cells generate the new 
tissue, facilitated by a scaffold providing the required atmosphere, while growth 
factors enhance tissue regeneration and ensure guidance towards the desired 
differentiation pathways [Ikada, 2006]. The following introduction will provide a brief 
overview over the three main factors, cells, scaffolds, and growth factors focusing on 
bone tissue engineering and on the types used within this thesis. 
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1.1.2 Cells as key factor in tissue regeneration  
Osteogenic cells enable a bone grafting material to form new bone [Shepherd and 
Best, 2011]. Therefore, the potential to generate bone is a prerequisite for the use of 
a cell type in skeletal tissue engineering. This is given for osteoblasts, embryonic 
stem cells, and other postnatal mesenchymal cells [Levi and Longaker, 2011].  
Embryonic stem cells (ESCs) are pluripotent and can therefore differentiate into any 
of the three germ layers (ectoderm, mesoderm, endoderm), but comprise the 
drawback of potential teratoma formation [Thomson et al., 1998]. Furthermore, their 
human blastocysts’ origin is accompanied by ethical issues [McLaren, 2007]. In 2006, 
the reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) was 
described in mice [Takahashi and Yamanaka, 2006] and was later transferred to 
human cells [Park et al., 2008; Takahashi et al., 2007; Yu et al., 2007]. The technique 
appears to be a promising alternative, generating pluripotent stem cells from 
autologous somatic cells. But it has to be considered that even syngeneic iPSCs 
were shown to cause immunogenic response [Zhao et al., 2011]. Besides ethical 
controversy, human embryonic stem cells (hESCs) and induced pluripotent stem 
cells (iPSCs) are currently under critical observation due to genomic alterations. A 
large number of duplications was reported for few of the tested hESCs, whereas 
iPSCs showed deletions in tumor-suppressor genes [Laurent et al., 2011]. 
Mesenchymal stem cells (MSCs) are an alternative cell type. They were named 
”mesenchymal“ due to their ability to differentiate into bone, tendon, connective 
tissue, cartilage, smooth muscle, adipose tissue, and skeletal muscle [Caplan, 1991; 
Caplan, 2005]. 
Multipotent adipose-derived stromal cells (ASCs) represent another suitable cell type. 
They are present in the lipoaspirate, and can thereby be easily harvested during the 
one million liposuctions being performed annually [Yoshimura et al., 2006]. ASCs can 
be used as an alternative for skeletal regenerative medicine as they exhibit 
comparable morphology, differentiation capacity, and phenotype to MSCs [Levi and 
Longaker, 2011]. 
Osteoprogenitor cells are an alternative due to their ability to differentiate into bone 
tissue and can be harvested from the periost. The limited availability hinders a 
broader use, whereas they are used during periodontal surgery as they can easily be 
harvested during this setting [Agata et al., 2007]. 
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All of the mentioned cell types need to be supplied with oxygen, being an intensively 
discussed factor regarding cellular behavior. Oxygen is known to be a metabolic 
substrate and a signaling molecule, but the role of oxygen on cellular behavior is not 
yet fully understood [Abdollahi et al., 2011]. While studies have shown that low 
oxygen concentrations help to maintain the multipotency of stem cells [Grayson et 
al., 2007], others identified low oxygen concentrations as a driving force for 
differentiation [Koay and Athanasiou, 2008]. In traditional cell cultures, the oxygen 
concentration is determined by the oxygen concentration of the ambient air being 
21 %. This is far above the physiological tissue oxygen concentration being 3 % in 
mean [Csete, 2005]. The ideal oxygen concentration for bone tissue engineering 
remains to be found. Static 3D cell culture experiments have shown, that even in 
small cylindrical scaffolds (9 mm diameter, 5 mm height) oxygen levels in the center 
dropped to 0 % within 5 days of culture, leaving no vital cells left and cells only 
survived in the periphery [Volkmer et al., 2008]. In living organisms, oxygen is 
provided by diffusion from surrounding blood vessels, but at a distance exceeding 
100 – 200 µm the oxygen supply is strongly reduced [Carmeliet and Jain, 2000]. In 
tissue engineering the use of oxygen generating biomaterials provides a possibility to 
overcome this limitation hindering the engineering of larger constructs [Oh et al., 
2009]. Oxygen generating biomaterials were shown to extend cell viability under 
hypoxic conditions and prevented necrosis of unvascularized tissue in vivo for 
several days [Harrison et al., 2007]. In contrast, hypoxia is a powerful stimulus for 
angiogenesis by stimulating the expression of VEGF [Rehman et al., 2004; 
Thangarajah et al., 2009]. Also aging has an effect on bone regeneration. Lu et al. 
reported that VEGF-expression, vascularization and bone repair of tibial fractures 
were decelerated in elder mice [2008]. However, the timeframe between implantation 
of tissue engineering constructs and neovascularization is critical regarding cell 
survival and the use of oxygen generating scaffolds might reduce this threat [Oh et 
al., 2009].  
Nonetheless, it was concluded that the application of cells alone is unlikely to be 
sufficient for bone regeneration. For large skeletal defects, a scaffold with adequate 
properties, such as size, shape, and mechanical strength is considered to be 
essential [Rose and Oreffo, 2002]. 
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1.1.3  Scaffolds as key factor in tissue regeneration 
In vivo, cells are embedded in extracellular matrix (ECM), guiding their development, 
arrangement, and regenerative abilities by specific signals, thus providing an 
appropriate environment for the cells. In tissue engineering, the role of the ECM 
needs to be executed by adequate scaffolds [Cunniffe and O’Brien, 2011]. A scaffold, 
used as a bone graft, needs to be osteoconductive, i.e. to “support the growth of 
bone over its surface” [Shepherd and Best, 2011]. Therefore, cellular adhesion to the 
scaffold is a prerequisite and can be modulated by the presence of adhesion 
domains in extracellular matrix proteins, containing the amino acid sequence Arg-
Gly-Asp (RGD) [Pierschbacher and Ruoslahti, 1987]. Scaffolds for bony application 
sites, coated with the RGD-sequence, enabled superior cell ingrowth in vivo [Eid et 
al., 2001]. Scaffolds further need to exhibit a certain porosity and pore 
interconnectivity to allow cell spreading, nutrient exchange, and vascularization 
[Hutmacher, 2000]. The porosity of trabecular bone has been reported to vary 
between 30 – 90 % [Carter and Hayes, 1977] and the pore size considered to be 
ideal for tissue engineering applications is in the range of 100 – 1000 µm [Friess and 
Werner, 2008]. Scaffolds should further be biodegradable and the timeframe required 
for biodegradation should match the rate of how fast new bone is formed [Shepherd 
and Best, 2011]. For the fabrication of tissue engineering scaffolds, amongst others, 
a wide range of different biomaterials, such as polyglycolide (PGA), polylactide 
(PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), calcium 
phosphates, or collagen can be used.  
Collagen is the most abundant structural protein in the body and main component of 
the ECM, expressed in various tissues. Amongst the different (currently more than 
20) collagens, collagen type I is the predominant type in the body, being expressed in 
bone, skin, tendon, ligaments, and cornea [Friess, 1998; Gelse et al., 2003]. It is the 
collagen type which is most frequently used in biomaterials research [Geiger et al., 
2003; Lee et al., 2001]. The overall mechanical performance of collagen-based 
biomaterials is poor. In order to enhance the mechanical properties and to reduce the 
in vivo degradation rate, collagen is crosslinked by either chemical (e.g. aldehydes, 
cardbodiimides), physical (e.g. dehydrothermal treatment, UV radiation), or 
enzymatic methods (e.g. transglutaminase, laccases, tyrosinases) [Friess, 1998; 
Griffin et al., 2002; Jus et al., 2011]. Furthermore, collagen can be combined with 
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calcium phosphate ceramics, e.g. hydroxyapatite, or tricalcium phosphate to form 
composite materials with enhanced mechanical properties [Al-Munajjed and O’Brien, 
2009; Bernhardt et al., 2008; Cunniffe et al., 2010; Geiger, 2001; Gelinsky et al., 
2008; Lyons et al., 2010]. A combination of collagen and hydroxyapatite was found to 
promote osteogenic differentiation of bone marrow derived stromal cells in vivo 
[Dawson et al., 2008] and provided superior defect healing properties in a rat cranial 
defect model [Lyons et al., 2010].  
Calcium phosphates themselves are frequently applied materials for bone repair as 
they exhibit a “chemical similarity to the mineral component of bone” [Shepherd and 
Best, 2011]. Hydroxyapatite (HA) and tricalcium phosphate (TCP) were used in 
numerous preclinical and clinical studies. They can be used in different 
morphologies, such as powders, cements, or granules [Geiger, 2001; Seeherman 
and Wozney, 2005; Sorensen et al., 2004]. TCP is resorbed faster compared to HA 
due to its higher solubility and osteoclastic remodeling [Allard and Swart, 1982; 
Bansal et al., 2009]. HA based scaffolds showed long term integration in cranical 
defects [Block and Thorn, 2000] and were successfully used in the reconstruction of 
the orbital roof [Allard and Swart, 1982]. Even long bone segmental defects (4-7 cm) 
were treated with the help of HA [Quarto et al., 2001]. TCP was successfully used as 
a bone filling material [Bansal et al., 2009; Erbe et al., 2001]. 
Moreover, PLGA (poly(lactic-co-glycolic acid)) is a compound frequently used for 
bone tissue engineering approaches. Constructs thereof can be adapted in shape 
and size to fit into the intended application site. 3D printed PLGA scaffolds seeded 
with osteoblasts formed a trabecular bone-like structure [Ge et al., 2009b] and in vivo 
studies successfully used PLGA scaffolds as bone graft materials [Ge et al., 2009a]. 
PLGA can further be used as a carrier material for growth factors like BMP-2 or 
parathyroid hormone in bone tissue engineering or other therapeutic proteins [Eliaz 
and Kost, 2000; Wei et al., 2004; Whang et al., 1998]. The degradation rates can be 
controlled by choosing the appropriate PLGA variant to obtain the desired release 
profile, but the degradation products can lead to pH decrease potentially influencing 
the stability of the incorporated drug [Göpferich, 1997; Lewis, 1990; Park, 1994]. All 
in all, collagen was named the „favoured carrier for BMPs“ [Rose and Oreffo, 2002]. 
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1.1.4  Growth factor delivery – bone morphogenetic proteins 
Osteoinductive growth factors guide the differentiation of precursor cell types into 
bone forming osteoblasts [Shepherd and Best, 2011]. Bone morphogenetic proteins 
(BMPs) have been studied most extensively in bone tissue engineering, but also 
others such as vascular endothelial, insulin-like, platelet-derived, fibroblast, and 
transforming-growth factor are involved in the fracture healing cascade [Dimitriou et 
al., 2011; Phillips, 2005]. BMPs are produced by MSCs, osteoblasts and 
chondroblasts during fracture repair. They act on MSC proliferation, differentiation, 
angiogenesis, and synthesis of extracellular matrix [AI-Aql et al., 2008]. Widely used 
in clinical applications are BMP-2 and BMP-7 [Biase and Capanna, 2005]. BMPs 
were further shown to enhance vascularization during fracture repair by stimulating 
the expression of VEGF [Deckers et al., 2002]. Two approved products using bone 
morphogenetic proteins are currently on the market: Medtronic’s INFUSE® bone 
graft, using rhBMP-2 for spinal fusion, non-union fractures, and oral maxillofacial 
applications [Medtronic Sofamor Danek, 2011], and Stryker’s OP-1/Osigraft [Stryker 
GmbH & Co. KG, 2008] using rhBMP-7 for treating non-union defects. Both products 
are based on a collagen carrier material, but rhBMP-7 stability and the mechanisms 
underlying binding and release remain to be shown. BMP-7 was comparable or 
superior to autologous bone grafts in tibial fracture repair [Friedlaender et al., 2001; 
Zimmermann et al., 2007]. With the help of BMP-7, a complete mandible was 
successfully engineered and applied as a bone transplant [Warnke et al., 2004].  
The strategies for delivery of BMPs comprise direct administration, scaffold-based 
delivery, and gene therapy, i.e. the delivery of genetically engineered cells 
expressing BMPs [Fischer et al., 2011]. Direct administration of BMPs results in fast 
clearance from the application site [Kirker-Head, 2000]. The scaffold-based approach 
is superior to application without scaffolds due to the increased retention at the 
application site [Geiger et al., 2003; Jeon et al., 2008]. For instance, combining BMP-
2 with a collagen scaffold increased the retention period compared to the application 
of BMP-2 in pure buffer [Geiger et al., 2003; Seeherman et al., 2003] and the 
combination of BMP-2 with inorganic calcium phosphate material further increased 
the retention period [Seeherman et al., 2003]. For this thesis, the scaffold-based 
delivery approach for rhBMP-7 was chosen. 
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1.2 Objectives of the thesis 
Aim of the thesis was to develop advanced biomaterials for bone regenerative 
purposes.  
Chapter 2 deals with the development and characterization of an in-situ hardening 
PLGA based system, resulting in an open-porous scaffold with a certain mechanical 
stability after administration into body fluids. The in-situ hardening formulation 
overcomes the complex ex vivo preparation scheme for 3D scaffolds, circumventing 
the drawback of decreased mechanical stability ascribed to injectable formulations. 
For further optimization and to combine osteoconductive and osteogenic working 
principles, the in-situ hardening system was further evaluated as a cell delivery 
system to obtain an injectable formulation, generating a porous and mechanically 
stable scaffold preloaded with cells.  
In Chapter 3 microbial transglutaminase was evaluated for enzymatic crosslinking of 
collagen with the aim to circumvent the toxicity of chemical crosslinkers typically used 
to enhance mechanical resistance and decrease the degredation rate of the collagen 
used for bioengineering [Speer et al., 1980]. Several methods to remove 
transglutaminase from collagen were evaluated and a method to demonstrate the 
absence of transglutaminase was established. 
Chapter 4 reports about the development of a defined loading procedure for rhBMP-7 
into collagen/ceramic composites. High binding efficiency needed to be ensured. 
Several quantification methods, including SEC, SDS-Page, and Western blot 
analysis had to be developed and a sterile filtration method, ensuring no loss of 
rhBMP-7, required for upcoming cell culture experiments, was established. The 
binding behavior of rhBMP-7 to the collagen/ceramic composites had to be assessed 
by extraction experiments. 
In Chapter 5 a formulation providing sustained release of oxygen was developed and 
incorporated into collagen/ceramic composite scaffolds. The purpose of this scaffold 
architecture was to engineer scaffolds enabling to maintain cell viability in larger 
tissue engineering constructs, where oxygen diffusion is a limiting factor regarding 
cell survival [Volkmer et al., 2008]. A sustained effect was desired with at the same 
time limited hydrogen peroxide formation. 
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Abstract 
Goal of the present study was to develop and to characterize in-situ hardening, 
porous PLGA based systems for their future application as bone grafting materials. 
Therefore, we investigated the precipitation behavior of formulations containing 
PLGA and a water-miscible solvent, DMSO, PEG 400, and NMP. To increase 
porosity, a pore forming agent (NaCMC) was added and to enhance mechanical 
properties of the system an inorganic filler (α-TCP) was incorporated. The behavior 
upon contact with water and the influence of the prior addition of aqueous media on 
the morphology of the corresponding hardened implants were investigated. We 
proved cell compatibility by live/dead assays for the hardened porous 
polymer/ceramic-composite scaffolds. The IsHS formulations can therefore be used 
to manufacture hardened scaffolds ex vivo by using molds with the desired shape 
and size. Cells were further successfully incorporated into the IsHS by precultivating 
the cells on the α-TCP-powder prior to their admixing to the formulation. However, 
cell viability could not be maintained due to toxicity of the tested solvents. But the 
results demonstrate that in vivo cells should well penetrate, adhere, and profilerate in 
the hardened scaffolds. Consequently, we consider the in-situ hardening system 
being an excellent candidate as a filling material for non weight-bearing orthopedic 
indications, as the resulting properties of the hardened implant fulfill indication-
specific needs like mechanical stability, elasticity, and porosity.  
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2.1 Introduction 
For critical-size defects resulting from tumor resection or traumatic injuries adequate 
filling materials are needed, as clinical studies showed that the implantation of filling 
materials can facilitate bone regeneration [Groeneveld et al., 1999]. Autologous bone 
grafting comprises the drawback of additional harvesting surgery with the risk of 
infections or donor-site morbidity [Kurz et al., 1989; Seiler and Johnson, 2000]. 
Allograft material like demineralized bone matrix exhibits the risk of immunologic 
rejection [Benichou, 1999] or transmission of infectious diseases [Moucha et al., 
2007]. Ceramic powders like tricalcium phosphate (TCP) or hydroxyapatite (HA) lack 
in cohesiveness, whereas preformed scaffolds need to be adapted to the desired 
shape and size of the application site prior to implantation. To overcome these 
limitations, implants based on PLGA (poly(lactic-co-glycolic acid)) have been 
developed. Tailor made properties and desired degradation profiles can be obtained 
by varying molecular mass [Park, 1994], lactic/glycolic acid ratio [Lewis, 1990], or 
esterification of carboxylic end-groups [Göpferich, 1997]. PLGA is FDA-approved for 
parenteral use, exhibits good biocompatibility and is used to design controlled drug 
release systems for therapeutic proteins [Eliaz and Kost, 2000] or antibiotics in bone 
regeneration [Price et al., 1996]. One drawback is the bulk erosion of PLGA leading 
to unfavorable acidic degradation products and pH decrease [Göpferich, 1997], 
which can be overcome by combining PLGA with basic calcium phosphates [Agrawal 
and Athanasiou, 1997]. According to the “diamond concept” as proposed by 
Giannoudis et al. an ideal bone substitute material should provide osteogenic cells, 
osteoconductive structures or scaffolds and growth factors besides mechanical 
stabilization and biological competence of the recipient [2007]. Thus, scaffolds for 
orthopedic indications require a certain porosity and pore interconnectivity to promote 
cell seeding, ingrowth, and proliferation [Hutmacher, 2000]. Porosity of trabecular 
bone is reported to be 30 – 90 % and a pore size of 100 – 1000 µm is considered to 
be ideal for the growth of bony tissue inside the implant [Carter and Hayes, 1977; 
Friess and Werner, 2008]. Human osteoblasts seeded on 3D printed PLGA formed a 
structure comparable to trabecular bone [Ge et al., 2009b] and 3D printed PLGA-
scaffolds were successful in vivo as bone graft materials [Ge et al., 2009a]. CAD-
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based 3D printed scaffolds are formed ex vivo to fill the designated void of any 
desired shape and size. An injectable in-situ hardening system could overcome this 
complex preparation scheme. Injectable formulations lack in mechanical stability 
required for bony applications. This lack of mechanical strength can be at least 
partially compensated by the addition of inorganic fillers [Pompe, 2008]. In the 
present study we developed a PLGA based, calcium phosphate enriched, in-situ 
hardening system (IsHS) with the purpose to allow bony regeneration right after 
administration by a self-setting mechanically stable osteoconductive scaffold with 
macro- and micro-porosity. Therefore, we examined compositions, based on the 
solvent-exchange-principle, where PLGA is dissolved in a water-miscible organic 
solvent [Hatefi and Amsden, 2002]. We furthermore studied the cell compatibility of 
the solvents used as well as of the IsHS and the hardened scaffolds. 
2.2 Materials and Methods 
Water used was highly purified from a USF ELGA PURELAB Plus UV/UF water 
purifier (Ransbach-Baumbach, Germany). All chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and analytical grade, unless otherwise stated. 
2.2.1  Materials 
Poly(D,L-lactic-co-glycolic acid) PLGA 50:50 Resomer RG 503H (RG 503H) or RG 
502H (RG 502H) (Boehringer Ingelheim, Ingelheim, Germany), Dimethyl sulfoxide 
(DMSO) and polyethylene glycol 400 (PEG) (Merck KGaA, Darmstadt, Germany), 1-
methyl-2-pyrrolidone (NMP, Sigma-Aldrich) and sodium carboxymethyl-cellulose 
(NaCMC) Blanose CMC 7HF PH (Hercules Int. GmbH, Zwijndrecht, Netherlands) 
with a particle size of 90 – 180 µm obtained by sieving were used. α-Tri-calcium-
phosphate (TCP) was obtained by heating β-tri-calcium-phosphate (Sigma-Aldrich) at 
1300 °C for 3 h followed by quench at room temperature. Phase-transition was 
monitored by X-ray diffraction and the desired particle size of 90 – 180 µm was 
obtained by sieving. Cell experiments were performed with human telomerase 
reverse transcriptase (hTERT) immortalized human mesenchymal stem cells (SCP-1) 
[Böker et al., 2008; Haasters et al., 2009; Polzer et al., 2011]. They were expanded in 
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DMEM GlutaMAX (GIBCO 21885, 476174, Invitrogen, Carlsbad, USA) 
supplemented with 10 % fetal bovine serum (FBS; Sigma, Munich, Germany) and 40 
IU/mL penicillin/streptomycin (PAA Laboratories GmbH, Pasching, Austria). 
2.2.2 Methods 
2.2.2.1 Precipitation studies 
1:2 and 1:3 (w/w) mixtures of RG 503H or RG 502H and NMP, DMSO, and PEG 
were heated to 80 °C in a drying chamber (Memmert GmbH, Schwabach, Germany) 
for 2 h until the polymer was completely dissolved. Defined amounts of phosphate 
buffered saline (137 mM NaCl, 2.7 mM KCl, 12 mM phosphate, PBS), pH 7.4 were 
added dropwise to the PLGA solutions in 6R glass vials (Fiolax clear, Schott AG, 
Mainz, Germany) and evaluated for visible precipitation. The precipitated samples 
inside the glass vials were further characterized concerning their moldability using a 
cylindrical piston (4 mm in diameter) with a Texture Analyser XTPlus (Stable 
Microsystems, UK) at 0.5 mm/s. The final endpoint of moldability was set, when more 
than 600 g were necessary for a 2.5 mm impression (~120 mN/mm²).  
2.2.2.2 IsHS-Preparation 
RG 503H or RG 502H solutions in organic plasticizer were mixed with various 
amounts of α-TCP and pore-forming agent (NaCMC) using a spatula. For detailed 
composition see Table 2-1. 
 
Table 2-1: Formulations of the different IsHS samples. 
Polymer: plasticizer = 1:2 Polymer: plasticizer = 1:3 
Polymer 22,0% 21,11% 20,00% Polymer 16,5% 15,83% 15,00% 
α-TCP 33,0% 31,67% 30,00% α-TCP 33,0% 31,67% 30,00% 
Solvent 44,0% 42,22% 40,00% Solvent 49,5% 47,50% 45,00% 
NaCMC 1,0% 5,00% 10,00% NaCMC 1,0% 5,00% 10,00% 
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The preparations (0.3 g for each sample) were either directly injected into 12 mL of 
PBS by means of a 1 mL syringe without needle or admixed (“preincubated”) with the 
maximum amount of PBS-amounts ensuring persistent moldability (see 2.2.2.1) prior 
to their application into PBS. The samples were incubated in a shaking water bath 
(Julabo SW 21; Julabo Inc., USA) at 37 °C for 24 h at 30 rpm and subsequently 
vacuum dried in a desiccator at 50 mbar (KNF Neuberger GmbH, Freiburg, 
Germany) for 48 h and analyzed with a Keyence VHX-500F digital microscope 
(Keyence Corporation, Osaka, Japan). 
2.2.2.3 Investigation of porosity 
Porosity was determined by the water evaporation method. Therefore vacuum dried, 
hardened IsHS based on RG 503H 1:3 (w/w) formulations (n=3) were weighed and 
soaked with water for 12 h at RT. Pore volume was calculated as (weight of 
saturated sample − weight of dried sample)/density of water. The theoretical volume 
of the dried sample without pores was calculated based on the densities of the 
ingredients of the respective formulation. Porosity was calculated as pore 
volume/(pore volume + volume of the dried sample). Furthermore, dry specimens 
were analyzed with a Keyence VHX-500F digital microscope (Keyence Corporation, 
Osaka, Japan) regarding pore size distribution. 
2.2.2.4 Mechanical behavior 
Vacuum dried, hardened IsHS based on RG 503H 1:3 (w/w) formulations (n=3) were 
cut to cuboids. Their heights (4.1 ± 0.9 mm) were determined with a caliper and 
samples were incubated for 2 h at 37 °C in PBS-buffer (pH 7.4). The samples were 
uniaxially compressed 3 mm with a cylindrical piston (4 mm in diameter) with a 
Texture Analyser XTPlus (Stable Microsystems, UK) at 0.25 mm/s. After vacuum 
drying in a desiccator at 50 mbar (KNF Neuberger GmbH, Freiburg, Germany) 
for 48 h the height was measured with a caliper. The required force for compression 
to 50 % of the initial height was investigated and relaxation as percentage of 
regained height after compression was calculated. For statistical analysis Student’s 
t–test was used. 
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2.2.2.5 Cell survival in plasticizers 
106 SCP-1 cells were cultivated in 6-well cell culture plates (BD Falcon, Bedford, MA, 
USA) for 24 hours. The medium was replaced by mixtures of plasticizer and cell 
culture medium. The experiment was run either at room temperature or after 
precooling the cells for 30 min at 4 °C and adding precooled plasticizer/cell culture 
medium mixtures at 4 °C. After incubation for 5 min live/dead assays were carried 
out. After double staining with fluoresceindiacetate (FDA) and propidium iodide-
solution (PI, 1 mg/mL Sigma-Aldrich) viable cells appear green and nonviable red, 
when analyzed with a laser scanning fluorescence microscope (LSM 510, Axiovert 
200M, Zeiss, Jena, Germany). Therefore, 10 mg of FDA were dissolved in 2 mL of 
acetone and diluted 1:500 in phosphate buffered saline (PBS). 0.5 mL of the final 
mixture of FDA/PI (1:1) were administered to each well after removal of the 
incubation medium and incubated for 1 minute. After washing with 0.5 mL of PBS the 
samples were analyzed with the fluorescence microscope. 
2.2.2.6 IsHS-Preparation for cell loading 
1:2 and 1:3 (w/w) mixtures of RG 503H or RG 502H and organic plasticizer NMP or 
DMSO representing 60 % of the final composition, were prepared in 6R glass vials 
(Fiolax® clear, Schott AG, Mainz, Germany). They were heated up to 80 °C in a 
drying chamber (Memmert GmbH, Schwabach, Germany) until the polymer was 
completely dissolved and subsequently quenched to room temperature. 30 % 
inorganic filler (TCP) and 10 % pore forming agent (NaCMC) were homogenously 
dispersed in the polymer solutions with a spatula. The following steps were carried 
out in a 4° C cold room with IsHS and SCP-1 cells precooled at 4° C. The scaffold 
matrix (n=3) was weighed on a glass petri dish (m = 0.3 g) and mixed with 106 SCP-1 
cells which were dispersed in the maximum DMEM cell culture medium content, 
determined according to 2.2.2.1. The putty system was subsequently transferred into 
a 6-well cell culture plate (BD Falcon, Bedford, MA, USA) containing 12 mL DMEM 
cell culture medium heated to 37 °C in a water bath (Julabo SW 21; Julabo USA 
Inc.). After 20 minutes of incubation the hardened, cell-enriched IsHS was removed, 
cut in halves with a scalpel and cell viability was investigated via live/dead assays 
(see 2.2.2.5). 
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2.2.2.7 IsHS-Preparation for cell loading via TCP-settlement 
6-well cell culture plates (BD Falcon, Bedford, MA, USA) were homogeneously 
covered with the amount of TCP that would make 30 % of the final IsHS-composition. 
106 SCP-1 cells, dispersed in the maximum DMEM cell culture medium content, 
determined according to 2.2.2.1 were seeded into each well and incubated for 24 
hours. 1:3 (w/w) mixtures of RG 503H and organic plasticizer NMP or DMSO 
representing 60 %, or PEG, representing 63.3 % of the final composition, were 
prepared in 6R glass vials. They were heated up to 80 °C in a drying chamber until 
the polymer was completely dissolved, subsequently quenched to room temperature 
and enriched by 10 % (5 % for PEG) pore forming agent (NaCMC) with a spatula. 
This composition was homogenously dispersed in the pre-seeded TCP/cell/DMEM-
mixture with a spatula. The putty system was subsequently transferred into a 6-well 
cell culture plate (BD Falcon, Bedford, MA, USA) containing 12 mL DMEM cell 
culture medium heated to 37 °C by means of a water bath. After 5 minutes of 
incubation for solvent exchange and further precipitation the hardened, cell-enriched 
IsHS was removed, cut in halves with a scalpel and cell viability was investigated 
with live/dead assay. 
2.2.2.8 Cell settlement on hardened IsHS 
For the preparation of IsHS-formulations 1:2 (w/w) mixtures of RG 503H and organic 
plasticizers NMP, DMSO, or PEG in 6R glass vials were heated up to 80 °C in a 
drying chamber until the polymer was completely dissolved and subsequently 
quenched to room temperature. 33 % α-TCP and 1 % NaCMC were admixed with a 
spatula. The preparations (0.3 g for each sample) were injected into 12 mL of PBS by 
means of a syringe and incubated in a shaking water bath at 37 °C for 24 h at 30 rpm 
and subsequently vacuum dried in a desiccator at 50 mbar (KNF Neuberger GmbH, 
Freiburg, Germany) for 48 h. The hardened scaffolds were completely soaked with 
ethanol (96 %) for disinfection. After ethanol evaporation, 300.000 SCP-1 cells were 
seeded onto each scaffold and cell culture was performed for 72 h before live/dead-
staining and microscopic analysis.  
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2.3 Results and Discussion 
2.3.1 Precipitation studies 
To evaluate the maximum loading capacity of aqueous medium in the later IsHS-
mixture as well as the overall in-situ hardening behavior precipitation studies were 
performed. The used organic plasticizers DMSO, NMP, and PEG are water miscible 
in any ratio. Water miscibility is a prerequisite for the fundamental working principle of 
the IsHS, which is the water exchange of the plasticizer leading to precipitation of the 
PLGA due to its insolubility in aqueous atmospheres [Hatefi and Amsden, 2002]. This 
principle is utilized in Atrigel and has been established by Dunn et al. [1998; 1990] 
amongst others as a drug delivery system [Patel, 2010]. The solvent-exchange 
process has even been investigated in vivo [Kempe et al., 2008]. The focus of the 
present study was to find an optimized formulation for the in-situ hardening system 
exhibiting high porosity while maintaining mechanical strength and high cell 
compatibility. As cells require aqueous medium, a certain water miscibility of the 
system is a benefit for successful cell penetration in vivo into an applied cell-free 
carrier or when pursuing a cell carrying system The addition of small volumes of PBS 
reflecting only a few percent of the IsHS mass always led to a visible initial phase 
separation at the admixing focus but the system cleared after gentle shaking for 
several minutes. With further admixing of PBS the precipitation manifested itself, but 
the system remained moldable with a spatula. The point when the force required for 
a 2.5 mm impression with a cylindrical piston (4 mm in diameter) exceeded 600 g 
was set as the endpoint of potential pre-admixing of PBS. This was considered 
acceptable for a surgeon during a surgical setting for adapting the shape to the 
desired dimensions. As can be seen in Figure 2-1 PLGA dissolved in PEG exhibits 
only low miscibility with PBS without visible precipitation of maximally 2 %. The NMP 
(~ 6 – 12 %) and DMSO (~ 5 – 12 %) based systems showed higher miscibility 
without precipitation with only marginal differences among the different formulations. 
The PBS amount which can be added until moldability is no longer given strongly 
depended on the chosen polymer and the plasticizer:polymer ratio. The values 
obtained for RG 502H based systems were higher due to the lower molecular weight 
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of the polymer and the resulting lower inherent viscosity. A higher plasticizer:polymer 
ratio kept the system moldable at higher PBS contents due to the plasticizing effect 
of PEG, NMP, and DMSO. The highest values were obtained for RG 502H dissolved 
1:3 in NMP. Up to 12.6 % (ref. to total solvent content) were tolerated without 
irreversible precipitation and up to 46 % PBS could be admixed to the system while 
formability was maintained. It is described that the application of PLGA injectables 
based on the solvent exchange principle into an aqueous surrounding is followed by 
the subsequent formation of a semi-solid implant [Matschke et al., 2002]. A semi-
solid state ensures an adequate formability of the PBS-admixed IsHS and can 
therefore be used during the timeframe of a surgical setting. 
 
 
Figure 2-1: PBS-amount added to Resomer RG 503H and RG 502H in different 
solvents without visible precipitation (grey bars) and with ongoing moldability (black 
bars). 
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2.3.2 IsHS-Preparation 
One basic requirement for the IsHS was high porosity inside the hardened IsHS and 
at the surface to allow nutrient exchange with the surrounding tissue at the site of in 
vivo application [Karande et al., 2004]. In addition, high water miscibility is desired to 
keep the concentration of the organic solvent low to maintain viability of incorporated 
and migrating cells. The system is furthermore expected to show sufficient 
mechanical stability to resist pressure from surrounding tissue. Compositions with 
RG 502H and a polymer:plasticizer ratio of 1:3 yielded dense, waxy clots and were 
discarded. Figure 2-2 shows images of cross-sections of DMSO-based formulations. 
Porosity increased with an increasing amount of NaCMC as pore-forming agent. 
 
 
Figure 2-2: Cross sections of incubated IsHS with DMSO as plasticizer; formulations 
with 1 % NaCMC: a RG 503H 1:2, b RG 503H 1:3, c RG 502H 1:2; formulations with 
5 % NaCMC: d RG 503H 1:2, e RG 503H 1:3, f RG 502H 1:2; formulations with 10 % 
NaCMC: g RG 503H 1:2, h RG 503H 1:3, i RG 502H 1:2. 
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The sample surfaces are shown in Figure 2-3, revealing that a higher NaCMC 
content provides a suitable way to avoid the formation of a dense layer at the surface 
which could hinder liquid exchange and cell migration. NMP-based formulations 
showed similar appearance (not shown).  
 
 
Figure 2-3: Surface of incubated IsHS with DMSO as plasticizer; formulations with 
1 % NaCMC: a RG 503H 1:2, b RG 503H 1:3, c RG 502H 1:2; formulations with 5 % 
NaCMC: d RG 503H 1:2, e RG 503H 1:3, f RG 502H 1:2; formulations with 10 % 
NaCMC: g RG 503H 1:2, h RG 503H 1:3, i RG 502H 1:2.  
 
In contrast, PEG-based formulations collapsed with 10 % NaCMC, whereas 
formulations with a 1:2 ratio (polymer:plasticizer) formed dense structures lacking in 
porosity. The best results for PEG-based systems were obtained for RG 503H based 
formulations with a polymer:plasticizer ratio of 1:3 (Figure 2-4). The standard 
incubation protocol consisted of direct injection into PBS. As an alternative, admixing 
the IsHS with the previously determined maximum PBS-amounts ensuring persistent 
moldability (see 2.2.2.1) prior to their application into PBS (“preincubated”) generated 
comparable morphology of the resulting specimens (Figure 2-4).  
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Figure 2-4: RG 503H-based IsHS with PEG 400 as solvent and 5 % NaCMC; 
standard incubation: a cross section, b surface; preincubated formulations: c cross 
section, d surface.  
 
This is in accordance with Brodbeck et al., who reported that water addition to PLGA 
dissolved in NMP leads to faster solvent exchange upon contact with water without 
influencing the morphology of the hardened product [1999]. RG 502H 1:2 and RG 
503H 1:3 with 10 % NaCMC for DMSO and NMP-based formulations and RG 
503H 1:3 with 5 % NaCMC with PEG as plasticizer appeared to be the most 
promising candidates. These formulations showed the desired porosity and high PBS 
amounts could be admixed while moldability was maintained. Consequently, they 
were selected further cell compatibility testing (see 2.2.2.7).  
2.3.3 Investigation of porosity 
The used pore-forming agent NaCMC is conventionally used as tablet disintegrant 
[Khan and Rhodes, 1975]. By expansion of NaCMC upon contact with water, an 
increasing NaCMC content led to increased volumes of the specimens with high 
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porosity. Figure 2-5 shows the gravimetrically determined water-uptake-factor (as 
multiple of the dry mass) as a measure of porosity, known as water evaporation 
method.  
 
 
Figure 2-5: Water-uptake of hardened IsHS as multiple of the dry mass of fully 
soaked hardened specimens based on RG 503H 1:3 (w/w) formulations.  
 
The total porosity of the resulting hardened specimens was calculated being 
81.2 ± 2.1 % for 1 % NaCMC, 94.3 ± 1.6 % for 5 % NaCMC, and 96.5 ± 0.4 % for 
10 % NaCMC. Khan and Rhodes reported that NaCMC adsorbed 50 % (w/w) water 
during 25 h of storage at 100 % relative humidity at 37 °C [1975]. With regards to that 
fact, porosity was calculated being 81.1 ± 2.1 % for 1 % NaCMC, 94.3 ± 1.6 % for 
5 % NaCMC, and 96.5 ± 0.4 % for 10 % NaCMC. In comparison, the porosity of 
trabecular bone is reported to vary between 30 and more than 90 % [Carter and 
Hayes, 1977]. A pore size between 100 and 1000 µm is considered as ideal for 
growth of bony tissue within the implant and minimization of fibrous tissue at the 
interface between implant and tissue [Friess and Werner, 2008]. As determined by 
microscopy (see 2.2.2.3) this was given for 88.4 ± 2.8 % of the pores with no 
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statistically significant difference among the formulations. No difference between the 
surface and the cross-section of the specimens was observed, what can be ascribed 
to the defined particle size of the NaCMC.  
2.3.4 Mechanical behavior 
The wet and therewith moldable specimens were uniaxially compressed and the 
required force for compaction to 50 % of the initial height was measured and divided 
through the contact area of the compacting punch. As shown in Figure 2-6, the 
mechanical strength strongly decreased with increasing porosity (see 2.3.3), 
achieved by higher NaCMC concentrations (p < 0.05).  
 
 
Figure 2-6: Compressive strength of fully soaked hardened specimens based on RG 
503H 1:3 (w/w) formulations. 
 
No statistically significant differences among the use of different plasticizers were 
observed. The highest value was obtained for the DMSO-based formulation 
containing 1 % NaCMC being 285 ± 125 mN/mm², which is around 10 times higher 
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than for mineralized collagen [Gelinsky et al., 2008] and around 6 times higher 
compared to a collagen/hydroxyapatite (50:50) composite material [Ciardelli et al., 
2010]. The lowest force of 1.8 ± 0.6 mN/mm² for compression to 50 % original height 
was required for the NMP-based formulation containing 10 % NaCMC. For 
completely soaked pure collagen-scaffolds values lower than 1 mN/mm² were 
reported [Geiger, 2001]. Tissue pressure is normally near 0 and pressures above 
1.3 – 4 mN/mm² can lead to inadequate perfusion [Whitesides et al., 1975]. A 
pressure of 4 mN/mm² would result in a compression of the developed scaffolds with 
NMP or DMSO and 5 % NaCMC or less to 74.4 % of their original height at most. 
Figure 2-7 illustrates that all samples were highly elastic as they relaxed to their 
dimensions prior to compression to 66 – 90 % depending on the formulation.  
 
 
Figure 2-7: Relaxation of previously compressed, fully soaked hardened specimens 
based on RG 503H 1:3 (w/w) formulations as % of regained former height; * scaffolds 
collapsed during vacuum drying. 
 
Higher NaCMC contents led to higher relaxations, statistically significant (p < 0.05) 
for the DMSO and NMP-based formulations with 1 % NaCMC compared to 5 or 
10 %. The most pronounced relaxation as percentage of regained height after 
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compression was obtained for the DMSO and NMP-based specimens containing 
10 % NaCMC with 89,4 ± 11.9 % and 90.2 ± 3.1 % respectively. The lowest value 
was observed for the 5 % NaCMC containing PEG-based specimens with 
27.9 ± 26.5 %. After compression and subsequent vacuum drying, the PEG-based 
specimens with 1 % NaCMC in the formulation were too brittle for further 
investigation. Regarding their compressive strength, elasticity, and high porosity we 
consider the NMP and DMSO-based formulations with 5 % NaCMC as ideal 
candidates as bone graft substitutes for non weight-bearing application sites. 
2.3.5 Cell survival in plasticizers 
Cell compatibility of the used organic solvents was consequently evaluated. Figure 2-
8 shows pictures obtained by fluorescence microscopy after live-dead staining of 
cells incubated for 5 min in mixtures of cell culture medium with 30 % and 60  % of 
PEG, NMP, and DMSO at 37 °C.  
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Figure 2-8: Live/dead assay of plasticizer-incubated SCP-1 cells after 5 min. 
incubation; a&b DMSO 60 % & 30 %, c&d NMP 60 % & 30 %, e&f PEG 60 % & 
30 %, g&h controls.  
 
Picture f shows several viable SCP-1 cells after 5 minutes incubation in cell culture 
medium containing 30 % PEG. All other incubation protocols at RT resulted in non-
viable cells. Consequently, cell survival in presence of plasticizer concentrations 
necessary to maintain a moldable IsHS (see 2.3.1) is not given. Higher temperatures 
are supposed to increase membrane permeability [Bischof et al., 1995] and cooling is 
an appropriate way to reduce metabolism [Ducommun et al., 2002]. Therefore, in an 
attempt to enhance viability the experiments were performed at 4 °C to induce a 
metabolic arrest of the cells and thereby extend their vitality. Figure 2-9 shows the 
results of live/dead-assay of the cell incubation with 30 and 60 % organic solvent 
performed at 4 °C.  
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Figure 2-9: Live/dead assay of plasticizer-incubated SCP-1 cells after 5 min. 
incubation at 4 °C; a&b DMSO 60 % & 30 %, c&d NMP 60 % & 30 %, e&f PEG 60 % 
& 30 %, g&h controls.  
 
SCP-1 cells were able to maintain their viability after incubation with 30 % DMSO or 
PEG after 5 minutes incubation at 4 °C (Figure 2-9 b & f), whereas cells were not 
able to resist 60 % solvent. Incubation with NMP did not leave adherent cells in the 
well behind. The LD50 for PEG 300 in rats is reported to be 17 g/kg and the solvent is 
known to cause necrotic reactions at the administration site [Smyth et al., 1950]. But 
tissue response was considered to be a mild chemical inflammation and damage was 
nonpermanent [Carpenter and Shaffer, 1952]. PEG 400 is FDA-approved for i.v. and 
i.m.-administration in concentrations of up to 20.3 % [FDA, 2011]. The LD50 for NMP 
is reported with 4 g/kg in rats [Lee et al., 1987]. For DMSO an LD50 of 12 g/kg in rats 
is reported [David, 1972]. DMSO is also used to reduce the damage resulting from 
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cryopreservation in concentrations of up to 10 % [Stylianou et al., 2006]. DMSO is 
FDA-approved for subcutaneous implants in a dosage of up to 104 mg. Assuming the 
body weight of a rat to be 300 g, the LD50 values would be exceeded by the 
administration of the following dosages of formulations with a ratio of 1:3 
(polymer:plasticizer) containing 5 % NaCMC: 9.8 g for PEG, 2.3 g for NMP, and 6.9 g 
for the DMSO based formulation. Taking those facts into account, we expected a 
certain, but less pronounced cell death in presence of the tested solvents. We expect 
the formulation to harm cells lethally in the first instance after administration. In vivo 
studies are required to evaluate the clinical relevance of this assumption. But after 
solvent exchange and thereby hardening a mechanically stable, open porous 
structure will result and allow a cellular ingrowth and nutrient exchange. 
Nevertheless, we performed cell incorporation tests to elucidate the vitality of the 
cells in the complete formulation. 
2.3.6 Cell incorporation 
We further evaluated the incorporation of cells into the previously optimized in-situ 
hardening system. Key challenge was to maintain cell viability in the presence of the 
organic solvents by keeping their concentrations at the lowest possible levels. On the 
one hand precipitation studies of the different polymer solutions revealed a maximum 
PBS-content in the solvent-phase of 35.9 % for RG 502H dissolved 1:2 in DMSO. On 
the other hand, biocompatibility testing of the solvents showed that only 30 % organic 
solvent can be tolerated. This leaves a gap where viability was uncertain. 
Consequently, IsHS were mixed with SCP-1 cells containing cell culture medium that 
represented the maximum that could be admixed retaining the formability of the 
systems. The cell viability results are depicted in Figure 2-10.  
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Figure 2-10: Live/dead assay of SCP-1 cells after direct addition to IsHS at 4 °C, a 
RG 502H, 1:2, 10 % NaCMC, DMSO, b RG 502H, 1:2, 10 % NaCMC, NMP, c RG 
503H, 1:3, 10 % NaCMC, DMSO, d RG 503H, 1:3, 10 % NaCMC, e RG 503H, 1:3, 
5 % NaCMC, PEG, f control.  
 
A very low number of cells maintained their viability. Moreover, the phenomenon can 
likely be ascribed to cells being dispersed in the medium and attaching to the 
specimen instantaneously prior to microscopic analysis. The overall incorporation 
efficacy is low, suggesting that the cells did not adhere to the material, whereas the 
contact time with the organic plasticizers is considered to be too long to maintain cell 
viability. To overcome this adherence problem and to shorten the contact time with 
the organic plasticizers, cells were precultivated for 24 h directly on the TCP-powder. 
Figure 2-11 shows that the adherence-problem was successfully overcome by the 
preseeding procedure, while the cells were not able to maintain their vitality. 
Therefore, we conclude that the high amounts of organic solvents hinder a direct 
incorporation of cells into the IsHS. The hardening system remains a promising 
biomaterial for non weight-bearing application sites due to its porosity, mechanical 
behavior, and convenient application mode. 
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Figure 2-11: Live/dead assay of IsHS with SCP-1 cells preseeded on the TCP-
powder at 4 °C, a RG 503H, 1:3, 10 % NaCMC, DMSO, b RG 503H, 1:3, 10 % 
NaCMC, NMP, c RG 503H, 1:3, 5 % NaCMC, PEG, d control.  
2.3.7 Cell settlement on hardened IsHS 
For the applicability of the system as a bone grafting material cellular adhesion and 
cell survival are prerequisites. This was investigated by cell seeding on hardened 
scaffolds prepared of the IsHS by solvent exchange and subsequent drying. Figure 
2-12 demonstrates excellent cell compatibility after 24 h solvent exchange and 
hardening of the IsHS. 
 
 
Figure 2-12: Live/dead assay of SCP-1 cells seeded on IsHS hardened in PBS for 
24 h at 37°C; a RG 503H, 1:2, 1 % NaCMC, DMSO, b RG 503H, 1:2, 1 % NaCMC, 
NMP, c RG 503H, 1:2, 1 % NaCMC, PEG. 
 
Thus, in vivo the materials will provide good scaffolds for tissue regeneration. The 
formulations could also be used to generate scaffolds ex vivo of the desired shape 
and size by using specific molds for solvent exchange.  
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2.4 Conclusion 
The aim of the present study was to develop an injectable, putty-like in-situ hardening 
system based on PLGA. The materials can be adapted to the desired size and shape 
for bony applications, what is especially beneficial for the augmentation of voids 
resulting e.g. from resections. It was of special interest to optimize porosity and 
mechanical strength of the hardened structure. In addition, a special focus was 
placed on the understanding of the interaction of the material with cells. On the one 
hand cell survival in the solvent based system was studied and on the other hand cell 
compatibility of the hardened structure with SCP-1 cells was tested. We investigated 
several polymers, solvents, and polymer:plasticizer-ratios. Mechanical properties 
were adapted by the incorporation of an inorganic filler and porosity was adjusted by 
admixing NaCMC as a pore forming agent. Semi-solid formulations were found, 
which, after solvent exchange hardened and provided highly porous 3D constructs 
while maintaining mechanical resistance to uniaxial compression, beneficial for 
cellular ingrowth. The addition of aqueous medium to the polymer-solution did not 
alter the morphology of the corresponding implants nor change the system from 
being a formable putty besides precipitation and increased viscosity. Cells were 
successfully incorporated into the formulation via cultivation on α-TCP prior to the 
final mixing with the remnant IsHS-formulation. However, the viability of the SCP-1 
cells could not be maintained during this procedure. We conclude that a cell-enriched 
in-situ hardening system based on PLGA cannot be realized with the organic 
solvents used in this study. Upon administration of the cell-free IsHS-formulation the 
contained solvent is expected to locally damage cells in the very beginning, but 
should soon provide a highly cell compatible environment. However, the clinical 
relevance of this phenomenon needs to be addressed in further in vivo studies. The 
developed formulations can furthermore be used to generate scaffolds ex vivo of the 
desired shape and size by using specific molds for solvent exchange. Cell 
compatibility of the hardened system is fully given and cells can penetrate the system 
and maintain their viability. Overall, an optimized formulation for a putty-like system, 
which generates a highly porous, mechanically stable scaffold at the site of 
application was successfully developed.  
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Abstract 
In the present study, we developed an enzyme-linked immunosorbent assay (ELISA) 
for microbial transglutaminase (mTG) from Streptomyces mobaraensis to overcome 
the lack of a quantification method for mTG. We further performed a detailed follow-
on-analysis of insoluble porcine collagen type I enzymatically modified with mTG 
primarily focusing on residuals of mTG. Repeated washing (4x) reduced mTG-levels 
in the washing fluids but did not quantitatively remove mTG from the material 
(p < 0.000001). Substantial amounts of up to 40 % of the enzyme utilized in the 
crosslinking mixture remained associated with the modified collagen. Binding was 
non-covalent as could be demonstrated by Western blot analysis. Acidic and alkaline 
dialysis of mTG treated collagen material enabled complete removal the enzyme. 
Treatment with guanidinium chloride, urea, or sodium chloride was less effective in 
reducing the mTG content.  
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3.1 Introduction 
Collagen is a widely used biomaterial for biomedical applications like wound healing 
sutures, spongy implants, injectable dispersions, or controlled release systems. 
However, a major drawback of sheets or porous systems made from collagen is the 
lack of mechanical stability. This deficiency may be overcome by applying external 
crosslinking to regain stability or to even provide mechanical strength beyond the 
natural capacity lost during the isolation processes [Friess, 1998; Friess and 
Schlapp, 2001]. Widely used chemical crosslinking methods comprise residue 
problems with potential or well-known toxicity [Speer et al., 1980]. Enzymatic 
crosslinking might help to circumvent this situation. Microbial transglutaminase (mTG) 
derived from Streptomyces mobaraensis is a commonly used enzyme in 
pharmaceutical research and food industry as well as in tissue engineering and 
biomaterials research [Besheer et al., 2009; Fontana et al., 2008; Garcia et al., 2008; 
O Halloran et al., 2006; Zhu et al., 1995]. It catalyzes the formation of a covalent 
amide bond between an ε-amino-group of a lysine residue and the γ-carboxamid 
group of a glutamine residue [Folk, 1980]. It is a 38 kDa non-glycosylated 331 amino-
acid protein with one single cysteine residue, which is essential for its catalytic 
activity [Ando et al., 1989; Kanaji et al., 1993]. Crystal structure and the catalytic 
scheme have been discovered [Kashiwagi et al., 2002] and an activity-assay for 
tissue type II transglutaminase has been developed [Raghunath et al., 1998]. The 
effects of transglutaminases in tissue engineering have been intensively studied 
[Zeugolis et al., 2010]. Cells seeded on mTG-treated collagen show better adhesion, 
proliferation, and osteogenic differentiation [Chau David et al., 2005]. It has been 
reported that treatment with mTG increases the storage modulus of chicken sternal 
collagen type II [O Halloran et al., 2006], enhances neovascularisation of wound 
healing constructs made of bovine calf skin type I collagen [Garcia et al., 2008] and 
increases tensile strength and melting temperature of porcine skin collagen 
type I [Chen et al., 2005]. However, in these studies, the obtained materials were 
analyzed without any purification and, thus, not considering potential residuals of 
mTG. Ciardelli et al. attempted to remove mTG by washing the specimens twice with 
water but did not elucidate, whether residuals were left [2010]. The question arises 
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whether the obtained results were due to mTG-mediated crosslinking of the collagen 
or due to other effects that can be ascribed to mTG-residuals. This has become even 
more important since Stachel et al. reported that mTG does not establish ε-(γ-
glutamyl)-lysine bonds in native collagen type I derived from both calf skin and 
bovine hide [2010]. Even though mTG seems to exhibit no cytotoxicity [Chen et al., 
2005; O Halloran et al., 2006], it might provoke severe immune responses as any 
foreign protein can. From the analytical point of view, the determination of the 
enzymatic activity of mTG has been established in the 1960s [Folk and Cole, 1965] 
but this procedure, however, cannot be utilized to detect residuals in mTG-treated 
materials due to the potential activity loss resulting from material processing. The 
present publication closes the described analytical gap in mTG-quantification 
developing a specific ELISA, which can detect mTG in presence of collagen. 
Furthermore, it helps to give more insight into the fate of mTG after its addition to the 
substrate, its interactions, removal, and potential residuals. 
3.2 Materials and Methods 
All water used was highly purified and deionized with the help of a USF ELGA 
PURELAB Plus UV/UF water purifier (Ransbach-Baumbach, Germany). All 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless 
otherwise stated. For Elisa, Maxisorp 96-well flat-bottom plates were purchased 
from Nunc Inc. (Roskilde, Denmark), rabbit anti-bacterial-transglutaminase antibody 
(A019) was from ZEDIRA GmbH (Darmstadt, Germany), mouse anti-bacterial-
transglutaminase antibody (Cov3C7) and biotinylated rabbit anti-mouse IgG were 
from Covalab (Villeurbanne, France), and streptavidin poly-HRP Calbiochem was 
obtained from Merck KGaA (Darmstadt, Germany). 
3.2.1 mTG modification of collagen 
Porcine-skin derived collagen-suspension was prepared according to Meyer et 
al. [2010]  and freeze-dried (Christ Epsilon 2-6D, Osterode am Harz, Germany) to 
obtain insoluble porcine collagen type I raw material. The dried collagen (nonxl) was 
dispersed in 800 mL Soerensen-buffer (pH 6.0) at a concentration of 0.5 % (w/w) as 
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transglutaminase is more active around neutral pH. AktivaWM transglutaminase 
(activity: 51.8 U/g) from Ajinomoto (Hamburg, Germany) was added at 2 g/L for “tgxl” 
samples and 5 g/L for “tgxl high” samples. The enzymatic activity therefore was 
20.7 U/g collagen for tgxl and 51.8 U/g collagen for tgxl high, respectively. The mTG-
preparation was used without further purification and therefore contained 99 % 
maltodextrin. The initial content of pure mTG in tgxl and tgxl high collagen was then 
calculated to be 0.4 % and 1 %, respectively. The dispersion was incubated at 30 °C 
for 2 h and centrifuged at 2739 g (Sigma 4K15, Osterode am Harz, Germany) after 
incubation. The supernatants (770 mL of the initial 800 mL) were removed, and pH 
values were measured before freezing the material at -40 °C for further ELISA-
analysis. The pellets were washed four times by resuspending each with 150 mL 
water (pH adjusted to 3.7 with concentrated acetic acid). This pH condition (pH 3.7) 
was chosen to ensure that both, collagen with an isoelectric point of 7.8 and mTG, for 
which an isoelectric point of 9 has been reported by Ando et al. [1989], show a highly 
positive net charge resulting in substantial repulsive interaction. After centrifugation, 
the washing solutions were collected, pH-values were measured, and the solutions 
were subsequently deep-frozen at -40 °C for further analysis. The mTG-modified 
collagen pellets were freeze dried. Collagen treated with either Kristallpur RC 0811 
maltodextrin “malto” (Hafen-Muehlen-Werke GmbH, Bremen, Germany) or heat 
inactivated mTG (95 °C, 45 min.) “inactivated” were processed in the same manner 
as tgxl-material to obtain references. 
3.2.2  Collagen sample preparation 
Samples were prepared by dispersing the different collagen materials (nonxl, tgxl, 
tgxl high, malto, inactivated) in water (pH adjusted to 3.7 with concentrated acetic 
acid) at a concentration of 2 % (w/w). After swelling for 4 h, the dispersions were 
homogenized with an ESGE immersion blender (Unold AG, Germany). Dispersion-
aliquots of 1.5 mL per well were distributed in Costar polystyrene 24-well plates 
(Corning Inc., Corning, USA) and freeze dried. 
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3.2.3  Melting temperature 
Melting temperatures were determined using a Mettler Toledo DSC821e differential 
scanning calorimeter. Therefore, 3 mg samples (n=3) were incubated with 10 µL 
PBS-buffer in 40 µL aluminum crucibles  (Mettler, ME-26763) for at least 2 h at room 
temperature and then heated from 20 to 90 °C with a heating rate of 10 K/min.  
3.2.4 Enzymatic degradation 
Collagen samples of 6 mg (n=3) were incubated in 1 ml TES-buffer (N-
tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, adjusted to pH 7.4 with 1 M 
sodium hydroxide) at 37 °C for one hour to allow wetting and swelling of the collagen. 
20 µg collagenase (Clostridium histolyticum type H, Sigma) was added to each 
sample and incubated for 2, 5, or 24 h. Samples were centrifuged with 186,000 g 
(Optima TLX-CA, Beckman Coulter, Brea, CA, USA) for 45 min at 4 °C and the 
supernatants were removed. Supernatants of the 24 h incubation were analyzed by 
ELISA and Western blot. To evaluate whether mTG was degraded by collagenase 
under these conditions, mTG alone was treated in the same way. After vacuum 
drying, the weight loss was determined gravimetrically. 
3.2.5 Tensile strength measurement 
For tensile strength measurements, strips of 10 x 50 mm displaying a height of        
3 - 5 mm (determined with a caliper) were manufactured by dispersing the collagen 
materials of interest in water (pH adjusted to 3.7 with concentrated acetic acid) at a 
concentration of 2 %, followed by swelling for 4 h, homogenization with an ESGE 
immersion blender (Unold AG, Germany) and freeze drying in polyethylene molds. 
Cutting with a scalpel rendered the desired dimensions. The obtained strips were 
incubated in PBS for at least 2 h at room temperature (RT). The wet specimens (n=6) 
were elongated with a Texture Analyser XTPlus (Stable Microsystems, UK) at a 
speed of 0.5 mm/s at RT until rupture and the highest force measured was divided 
through the cross-section areas of the corresponding collagen strips.  
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3.2.6 ELISA-procedure 
For the development of an ELISA for mTG, all incubation steps were performed at 
RT on an orbital shaker (Titramax 101, Heidolph Instruments GmbH, Schwabach, 
Germany) at 150 RPM unless otherwise stated. Microplate wells were coated for 4 h 
with 100 µL of 2 µg/mL rabbit anti-mTG antibody (ZEDIRA) in 50 mM carbonate 
buffer (pH 9.6). Plates were rinsed five times with wash/dilution buffer (10 mM 
phosphate buffer (pH 7.4) containing 0.1 % polysorbate 20 and 0.5 M sodium 
chloride) and blocked with 200 µL of 0.5 % BSA in wash/dilution buffer for one hour 
followed by five washing steps with wash/dilution buffer. For preparation of the 
calibration curves, mTG-preparation was diluted to concentrations between 100 
ng/mL and 5 µg/mL (i.e. mTG concentration: 1-50 ng/mL) in TES-buffer (N-
tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid) adjusted to pH 7.4 with 1 M 
sodium hydroxide and incubated for 24 h at 37 °C in the presence or absence of 
collagenase (19.6 µg/mL). Calibration standards and protein samples were added to 
the wells (100 µL) and incubated overnight at 4 °C without agitation. After rinsing five 
times with wash/dilution buffer, 100 µL of mouse anti-mTG antibody (Covalab; 1 
µg/mL in wash/dilution buffer) were added to each well and incubated for 1 h and 
subsequently washed five times. 100 µL of biotinylated IgG H + L (Covalab; 1 µg/mL 
in wash/dilution buffer) was added to each well and incubated for 1 h, followed by five 
washing steps and the subsequent addition of 100 µL streptavidin poly-HRP (Merck; 
0.1 µg/mL in wash/dilution buffer). After one hour of incubation, the plate was rinsed 
five times with wash/dilution buffer before the addition of 100 µL citric acid buffer 
solution (pH 5) containing 0.005 % H2O2 and 0.5 mg/mL o-phenylenediamin. The 
reaction was stopped by adding 100 µL of 1 N H2SO4 after 6 min, and the 
absorbance was measured at 490 nm with a FLUOstar Omega microplate reader 
(BMG LABTECH GmbH, Offenburg, Germany). 
3.2.7 Western blot analysis 
Samples were prepared according to 3.2.4 or without the addition of collagenase. 
Standard Laemmli sample buffer was added, and samples were boiled for 5 min at 
95 °C. Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-Page, Bio-
Rad, Munich, Germany) was performed and separated proteins were transferred 
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onto Hybond-ECL nitrocellulose membranes (Amersham Biosciences, Freiburg, 
Germany) by tank electroblotting. Membranes were blocked with bovine serum 
albumin (Sigma Aldrich). A rabbit polyclonal anti-mTG antibody (1:1,000, overnight 
incubation) from ZEDIRA (Darmstadt, Germany) was used as primary antibody. For 
detection, horseradish peroxidase-labeled goat anti-rabbit antibody (1:10,000, 2 h 
incubation) from DIANOVA (Hamburg, Germany) and ECL Plus Western Blotting 
Detection Reagent from GE Healthcare (Munich, Germany) were used. The 
appearing luminescence was detected by exposure (1 min.) of the membrane to an 
X-ray film (Super RX, Fuji, Düsseldorf, Germany), which was subsequently 
developed with a Curix 60 developing system (AGFA-Gaevert, Cologne, Germany). 
3.2.8 Dialysis 
Dialysis was performed to reduce mTG concentration in tgxl samples. Collagen 
material (tgxl) and mTG as reference were dispersed at concentrations of 10 % in 
HCl (pH 2) or NaOH (pH 12). After swelling for 2 h, the materials were placed in 
Spectra/Por PVDF membranes with a 500 kDa cut-off (Spectrum Laboratories Inc., 
Rancho Dominguez, CA, USA) and dialyzed in three consecutive steps (3 h, 18 h, 
and 3 h) against 1.5 L HCl (10mM, pH 2) or NaOH (10 mM, pH 12) per g collagen or 
mTG, respectively. The dialyzed samples were freeze dried to obtain material for 
Western blot and ELISA determination after enzymatic degradation. As reference, 
the materials (tgxl and mTG) were treated accordingly at pH 2 or pH 12 without 
dialysis. 
3.2.9 Washing with additives 
Nonxl and tgxl collagens were dispersed at a concentration of 1 % (m/m) in 100 mL 
water containing either 1 M sodium chloride, guanidinium chloride, or urea with an 
ESGE immersion blender (Unold AG, Germany) and incubated for 18 h at RT. The 
dispersions were sonified for 5 min after 1, 16, and 17 h using a USC1200TH 
ultrasonic device (VWR, Darmstadt, Germany). After centrifugation at 2739 g (Sigma 
4K15, Osterode am Harz, Germany), the supernatants were removed and the 
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collagens were washed twice with 100 mL water. Finally, the collagen materials were 
lyophilized and analyzed by Western blot (see 3.2.7).  
3.3 Results and Discussion 
3.3.1 Melting temperature 
The melting temperature (Tm) or denaturation temperature is a parameter obtained 
during DSC-analysis of collagen samples. Tm strongly depends on the hydration of 
the collagen molecules. This hydration obviously depends on the water content of the 
samples [Miles and Ghelashvili, 1999; Zeugolis and Raghunath, 2010] and Tm 
increases with decreasing water content. But Tm also increases with increasing 
crosslinking degree [Miles et al., 2005]. To compare different crosslinking degrees of 
the collagen samples, the measurements were performed in the presence of an 
excess of water. Thus, a fully hydrated state is achieved, and differences caused by 
a different water content on Tm can be ruled out [Zeugolis and Raghunath, 2010]. 
The starting material used in our studies displayed a Tm of 60.1 ± 0.6 °C. This Tm is in 
agreement with native fibrillar collagen. The Tm for mTG-treated collagen (tgxl) was 
58.6 ± 0.5 °C. The melting temperature for “tgxl high” material was 58.4 ± 0.9 °C. 
This finding is in accordance with Collighan et al. who previously reported no effect 
on Tm for mTG and guinea pig liver transglutaminase (gTG) treatment of bovine hide 
or soluble rat collagen [2004]. Furthermore, the results correspond to the findings of 
Stachel et al. who reported that acid soluble collagen type I does not act as a 
substrate for mTG in the native state [2010]. However, Ciardelli et al. presented 
contradictory results revealing an increase of Tm by ~18 K for acid soluble calf skin 
collagen type I incubated with mTG (0.025 U/mg of protein) for 30 min at 37 °C 
[2010]. Since these latter authors used an incubation temperature of 37 °C, their 
results are again in good agreement with the findings of Stachel et al. who reported 
that mTG-derived crosslinks are formed at 37 °C, whereas they are not established 
at 30 °C incubation temperature [2010]. Taking these findings into account, the effect 
of mTG-treatment of collagen on Tm depends on the raw material being soluble or 
insoluble, on the incubation temperature as well as on alkaline or acidic 
pretreatments. Furthermore, in the case of the insoluble, acid derived porcine 
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material presented here, the crosslinking degree of the raw material is already at a 
high level and incubation temperature was low to maintain its native state. Therefore, 
mTG-treatment did not lead to a further increase in Tm. 
3.3.2 Enzymatic degradation 
For collagen material characterization, the resistance to enzymatic degradation by 
collagenase is a commonly used in vitro model. The gravimetrical determination is an 
established method since the work of Olde Damink et al. [1995; 1996]. Rault et al. 
showed that crosslinking of calf skin collagen with hexamethylene-diisocyanate 
(HMDC) and 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC) reduces 
enzymatic degradation [1996]. In Figure 3-1, the degradation rate of collagen is 
presented as a function of time.  
 
 
Figure 3-1: Degradation rates as a function of time of collagen raw material (nonxl) 
and mTG-treated collagen material (tgxl (0.004 g mTG/g collagen) & tgxl high (0.01 g 
mTG/g collagen)) subjected to 20 µg Clostridium histolyticum collagenase per 6 mg 
collagen. 
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After 2 and 24 h, the degraded amount is not influenced by mTG-treatment, 
contradicting Ciardelli et al. who reported reduced enzymatic degradation by ~50 % 
for calf skin collagen type I incubated with mTG (0.025 U/mg of protein) for 30 min at 
37 °C [2010]. However, after 5 h of incubation, the values of the samples that had 
been modified with the higher mTG-concentration indicate a slightly, but not 
significantly, higher resistance to collagenase. It is important to note that 
ultracentrifugation was mandatory to obtain meaningful data, whereas centrifugation 
at only 2739 g did render irreproducible and varying results. 
3.3.3 Tensile strength 
Figure 3-2 shows the displacement data of the nonxl and tgxl collagen strips during 
their elongation until rupture. The highest force obtained for each sample was taken 
to calculate the force upon rupture of the wet strips, which is presented in Figure 3-3. 
 
Figure 3-2: Displacement-data (0.5 mm/s) of elongated wet collagen strips (2 % 
collagen content), raw material (nonxl) and mTG-treated collagen (tgxl (0.004 g 
mTG/g collagen)) recorded with a Texture Analyser XTPlus. 
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Figure 3-3: Force upon rupture of wet collagen samples: untreated material (nonxl), 
mTG-treated collagen (tgxl (0.004 g mTG/g collagen), tgxl high (0.01 g 
mTG/g collagen), heat inactivated) and maltodextrin-treated collagen. 
 
The maximum force increased from 3.7 mN/mm² for the unmodified insoluble 
collagen to 16.3 mN/mm² for the mTG-treated tgxl material. The difference was 
proven to be statistically significant (p < 0.01) using a t-test. The general finding of 
increasing tensile strength by mTG-treatment is in accordance with literature, even 
though some of the reported data in literature lack control values for untreated raw 
material [Chen et al., 2005]. The increase in tensile strength being 440 % for the 
mTG-treated material is remarkable considering that it cannot be ascribed to the 
formation of ε-(γ-glutamyl)-lysine bonds, which is the typical reaction product of mTG-
catalysis [Folk, 1980], since Stachel et al. showed that these bonds are not 
established in native acid soluble bovine calf skin collagen type I under the tested 
conditions [2010] and insoluble collagen material should be a less suitable substrate. 
Freeze-drying might induce crosslinking by dehydrating conditions, but the nonxl 
material as well as the controls (maltodextrin only and heat inactivated 
Results and Discussion   51 
 
transglutaminase) was freeze dried according to the same protocol. The tensile 
strength values obtained for collagen treated with inactivated mTG or maltodextrin 
were similar to the nonxl material. Therefore, we can exclude a contribution of the 
freeze-drying steps to the increased tensile strength. What in fact increases tensile 
strength of the mTG treated collagen samples can only be hypothesized. We assume 
that mTG itself interacts with the collagen leading to better coherence. The tgxl high 
collagen exhibited a tensile strength comparable to the untreated material. After 
incubation with mTG, the dispersion appeared grainy and homogeneity could not be 
achieved during treatment with the immersion blender. Therefore, finding the ideal 
incubation conditions for modification with mTG is of crucial interest for material 
modification. After dialysis at pH 2 or pH 12, a tensile strength-determination is not 
feasible due to amide-bond hydrolysis occurring under these conditions that led to a 
strong decrease in tensile strength (data not shown).  
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3.3.4 Western blot analysis 
Western blot analysis was performed to evaluate, whether the washing steps enable 
the removal of mTG from the treated collagen material, and to gain insight into the 
type of interactions between collagen and mTG.  
 
 
Figure 3-4: Western blot, samples marked with (*) were not subjected to collagenase; 
a collagen raw material (nonxl), mTG-treated collagen (tgxl (0.004 g 
mTG/g collagen)), mTG-only, collagenase-only, collagen treated with heat inactivated 
mTG (inactivated) and maltodextrin-only control; b dialyzed mTG (Dia mTG) and 
dialyzed mTG-treated collagen (Dia tgxl) at pH 2 & 12 and undialyzed controls; c 
mTG-treated collagen (tgxl (0.004 g mTG/g collagen)) after washing with NaCl, urea 
or guanidiniumchloride and controls. 
 
Figure 3-4a shows a band for mTG at around 38 kDa, which is in accordance with 
previously reported results [Ando et al., 1989]. The mTG band is equally present in 
the enzymatically degraded tgxl collagen (lane 2 from the left) as well as in the tgxl 
sample not treated with collagenase (lane 6 from the left). As expected, mTG was not 
detected in the nonxl materials or controls. Obviously, mTG was not degraded by 
collagenase under the tested conditions and was therefore still accessible for 
analytical methods. Furthermore, the results show that the enzyme could not be 
quantitatively removed during washing steps. The distinct mTG band in the non-
degraded tgxl material revealed that mTG was not completely removed from mTG-
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treated collagen materials by four washing steps with water (pH adjusted to 3.7 with 
concentrated acetic acid). A clear quantification was not feasible, but the band 
intensity indicated the presence of substantial amounts of mTG. Microbial 
transglutaminase was not covalently bound to collagen as it could still be separated 
during electrophoresis.  
3.3.5 ELISA of washing solutions 
Despite numerous washing steps with water (pH adjusted to 3.7 with concentrated 
acetic acid), Western blot analysis rendered considerable amounts of mTG that 
remained in the tgxl-material. Quantification of mTG in the incubation medium after 
mTG-modification as well as in the washing fluids (see 3.2.1) should allow the 
calculation of the total amount of mTG that had been removed from the reaction 
mixture and consequently the mTG-amount remaining in the tgxl material. Figure 3-5 
demonstrates the decrease of mTG-concentration in the washing fluids with each 
washing step.  
 
Figure 3-5: Concentration of mTG in incubation-solution and in the washing fluids 
(washing 1-4) of mTG-treated collagen (tgxl (0.004 g mTG/g collagen) & tgxl high 
(0.01 g mTG/g collagen)) determined by ELISA. 
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The concentration determined in the supernatant after incubation and centrifugation 
was 8.54 µg/mL ± 0.68 µg/mL for tgxl and 16.80 µg/mL ± 2.68 µg/mL for tgxl high, 
respectively, whereas the initial concentration of mTG added for modification was 
either 20 µg/mL or 50 µg/mL. The third and the fourth washing step could only 
remove marginal amounts of the enzyme. The total amount of mTG that had been 
removed by all of the performed centrifugation and washing steps was 42.5 ± 7.8 % 
for the treatment leading to tgxl and 33.2 ± 16.1 % for the treatment leading to tgxl 
high. From these values, the residual amount of mTG in the collagen materials, 
based on the initial mTG amount during incubation, 0.4 % for tgxl and 1 % for tgxl 
high, can be calculated to be 0.23 ± 0.04 % mTG in the tgxl-collagen material and 
0.66 ± 0.16 % mTG in the tgxl high collagen material, assuming that collagen itself 
was not removed during washing. This finding confirms the Western blot observation 
that mTG cannot be quantitatively removed by washing steps. The pH-value 
decreased with each washing step from 5.9 to 4.1 to 3.7 and finally to 3.7. This 
ensures that both, collagen with an isoelectric point of 7.8 and mTG, for which an 
isoelectric point of 9 has been reported by Ando et al. [1989], show a highly positive 
net charge resulting in substantial repulsive interaction. Additionally, Western blot 
analysis proved that the interaction is non-covalent (see 3.3.4). Furthermore, 
hydrophobic interactions are expected to be less pronounced between the two rather 
hydrophilic molecules. Consequently, we conclude that mTG is mechanically 
entrapped in a network created by its own catalytic activity in the mTG-treated 
collagen materials. 
3.3.6 ELISA of collagen samples 
To confirm the amount of mTG calculated to be still present in the collagen after 
reduction of the enzyme by washing steps, a direct quantification method for mTG in 
the collagen was evaluated. Therefore, the collagen material needed to be 
hydrolyzed by collagenase. Additionally, it had to be clarified whether or not 
collagenase interfered with the ELISA. Two calibration curves of mTG were 
prepared, one in the presence and one in the absence of collagenase. These curves 
are presented in Figure 3-6. 
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Figure 3-6: ELISA calibration curves (mTG-quantification) in the absence and in the 
presence of Clostridium histolyticum collagenase type H (20 µg collagenase, 24 h 
incubation, 37 °C). 
 
As can be seen, no significant difference was observed, confirming that mTG is not 
degraded by collagenase under the tested conditions (mTG degraded according to 
3.2.4) and that the enzyme is still accessible for Western blot and ELISA analysis. 
Therefore, the desired samples were enzymatically degraded (see 3.2.4) and mTG 
concentrations in the supernatants of the 24 h samples were determined with the 
newly developed ELISA after 1:1000 dilution. Nonxl collagen samples treated with 
the same conditions served as blanks. Table 3-1 shows the residual mTG amounts 
determined being 0.157 ± 0.008 % in the tgxl collagen and 0.406 ± 0.004 % in the 
tgxl high samples. These amounts are lower than the calculated values based on 
washing fluid concentrations (see 3.3.5). This indicates a removal of collagen during 
washing procedure creating a systematic error of the calculation. The direct 
quantification of mTG in the collagen samples is therefore regarded as superior and 
much more reproducible considering the standard deviations.  
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Table 3-1: mTG content in mTG-treated collagen before and after washing (tgxl 
(0.004 g mTG/g collagen) & tgxl high (0.01 g mTG/g collagen)). 
 tgxl tgxl high 
Before washing 0.398 % 0.990 % 
After washing 0.157 ± 0.008 % 0.406 ± 0.004 % 
3.3.7 Dialysis 
Our findings obtained so far clearly show that mTG could not be quantitatively 
removed at pH 3.7 although numerous washing steps were performed but instead 
remained in the mTG-treated collagen material to a high extent. As an alternative 
approach, a dialysis procedure was carried out to remove unbound mTG by means 
of a concentration gradient, enforced by application of either more acidic (pH 2) or 
strong alkaline conditions (pH 12). ELISA quantification of mTG in dialyzed collagen 
samples after degradation by collagenase revealed that mTG could not be detected 
in mTG-modified collagen material at both pH conditions during dialysis. This finding 
indicates that mTG is removed by these dialysis procedures. Furthermore, Western 
blot analysis after enzymatic degradation by collagenase (see 3.2.4) showed, that 
mTG was no longer present in the mTG treated materials and therefore had been 
quantitatively removed by the dialysis procedures (Figure 3-4b, lanes 1&2 from the 
left). Although treatment at pH 2 led to partial fragmentation of mTG (Figure 3-4b, 
lane 7 from the left) and treatment at pH 12 caused partial aggregation (Figure 3-4b, 
lane 8 from the left), mTG remained detectable for Western blot analysis. Treatment 
of tgxl collagen at pH 2 or 12 without dialysis was not able to quantitatively remove 
mTG (Figure 3-4b, lanes 3&4 from the left). However, these harsh pH conditions led 
to a decrease in tensile strength due to amide bond hydrolysis (data not shown) and 
thereby interfered with the beneficial use of mTG. 
3.3.8 Washing with additives 
The understanding of the effects of specific ions on proteins is currently changing. 
There is increasing evidence that salting-in and salting-out effects of ions on proteins 
need to be ascribed to ion-protein and ion-shell-water-molecule interaction rather 
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than on ions changing the water structure and thereby affecting protein behavior 
[Zhang and Cremer, 2006]. To test whether the reduction of ionic interactions may 
enable mTG removal from the collagen samples, the collagen materials were 
subjected to washing with sodium chloride, guanidinium chloride, or urea. Western 
blot analysis showed that the mTG content in tgxl collagen increased in the following 
order: guanidinium chloride < urea < sodium chloride (Figure 3-4c). Although the 
used additives are known to have a lyotropic effect on collagen [Ranganayaki et al., 
1982; Russell and Cooper, 1972] only treatment with guanidinium chloride seems to 
be an effective tool to decrease mTG content but is less effective than dialysis (see 
3.3.7).  
3.4 Conclusion 
In the present study, we investigated the effects of Streptomyces mobaraensis 
derived transglutaminase (mTG) treatment on insoluble porcine skin collagen type I. 
The results showed neither increased melting temperatures nor reduced enzymatic 
degradation assuming that the tested material is an improper substrate for mTG. The 
use of soluble collagen would have been beneficial for that purpose. Nevertheless, 
an increase in tensile strength was detected demonstrating a significant effect on 
material characteristics, even though native collagen type I is not a good substrate 
for mTG regarding the installation of ε-(γ-glutamyl)-lysine bonds under the tested 
conditions [Stachel et al., 2010]. To address the question whether mTG could be 
removed by numerous washing steps, a Western blot analysis of the collagen 
materials was performed, revealing that mTG was still present in mTG-treated 
collagen material. The Western blot analysis further showed that mTG was not 
covalently bound to the collagen material and that it was not degraded by Clostridium 
histolyticum collagenase type H being still accessible for further analysis. To 
determine the amount of mTG that can be removed via centrifugation and washing, 
an enzyme-linked immunosorbent assay (ELISA) was developed to quantify mTG in 
the washing solutions. ELISA-analysis showed that mTG could only be partially 
removed by centrifugation and washing. It was shown by the direct quantification 
after degradation by collagenase that around 40 % of the initially applied enzyme 
remained in the mTG-treated collagen materials. To further reduce mTG-residuals, 
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dialysis procedures at acidic or alkaline pH and incubation with different additives 
were performed. Western blot analysis showed that especially guanidinium chloride 
treatment reduced the mTG content. The dialysis procedure was superior to all other 
treatments and enabled to quantitatively remove mTG. However, this method 
comprises the drawback of amide bond hydrolysis leading to decreased tensile 
strength. These findings strongly suggest that future studies using transglutaminase 
for the “crosslinking” treatment of collagen should address potential residuals of mTG 
and investigate, whether observed effects are due to mTG-induced changes of the 
collagen structure or due to remaining transglutaminase itself. If mTG cannot be 
quantitatively removed, the question of potential immunogenicity of mTG needs to be 
addressed in future studies.  
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4 rhBMP-7 in Collagen/Ceramic Composites – 
Incorporation, Quantification, and Recovery 
 
Abstract 
In the present study, a defined loading procedure for rhBMP-7 into collagen/ceramic 
composites ensuring high binding efficiency was established. An SEC quantification 
method for rhBMP-7 was developed, but failed detecting the very low rhBMP-7 
concentrations in presence of an excessive of collagen fragments. In the silver-
stained SDS-Page, rhBMP-7 signals were also covered by collagen. A Western blot 
analysis enabled to quantify rhBMP-7 in the presence of collagen and to determine 
the loss upon sterile filtration. For upcoming cell culture experiments, a defined and 
aseptic loading procedure of rhBMP-7 into collagen/ceramic composites was 
established. For the analysis of the binding behavior, methods to extract high 
amounts of rhBMP-7 from the carrier materials were developed. Arginin/histidine 
buffer pH 6.5 was the most effective rinse liquid to remove rhBMP-7 and enabled to 
recover 32.7 ± 12.7 % from the collagen/ceramic composites. Detailed Western blot 
analysis showed a synergistic binding capacity of collagen/ceramic composites for 
rhBMP-7 compared to the individual components, collagen and biphasic calcium 
phosphate. Extracted rhBMP-7 showed no signs of degradation. The rhBMP-7 
loaded collagen/ceramic composites are therefore considered to be promising 
functionalized biomaterials for further cell culture experiments. 
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4.1 Introduction 
For successful bone healing, besides a regenerative capacity of the recipient 
organism, the following prerequisites are demanded according to the diamond 
concept proposed by Giannoudis et al.: an osteoconductive structure, sufficient 
mechanical stability, osteogenic cells and growth factors [2007]. Marshall Urist 
discovered bone induction after implanting demineralized bone segments into rabbits 
[1965]. Bone inducing factors, which were later named bone morphogenetic proteins 
(BMPs), were held responsible for this observation. BMPs belong to the transforming 
growth factor-ß (TGF-ß) superfamily, except BMP-1 belonging to the group of 
metalloproteinases [Hofbauer and Heufelder, 1996]. During fracture repair BMPs 
recruite pluripotent stem cells and conduct the ossification by stimulating osteogenic 
and chondrogenic differentiation [Bostrom et al., 1995; Shen et al., 2010]. Of crucial 
interest for the clinical success of BMPs is an adequate retention at the site of 
application by carrier materials [Geiger et al., 2003; Jeon et al., 2008]. The 
combination of BMP-2 with a collagen scaffold significantly increases the retention 
period compared to the application of BMP-2 in pure buffer [Geiger et al., 2003; 
Seeherman et al., 2003]. The combination of BMP-2 with inorganic calcium 
phosphate material further prolongs the retention period [Seeherman et al., 2003] 
and reduces BMP-2 losses during implantation due to squeezing of the flexible 
collagen systems [Geiger, 2001]. The second clinically used BMP, BMP-7, has 
shown its comparability or superiority to autologous bone grafts in various studies 
without incidences of local or systemic toxicity or ectopic bone formation 
[Friedlaender et al., 2001; Vaccaro et al., 2008; Warnke et al., 2004; Zimmermann et 
al., 2007]. Osigraft® is a commercially available BMP-7 preparation, consisting of 
3.5 mg rhBMP-7 and 1 g bovine collagen which is reconstituted with 0.9 % (w/v) 
sodium chloride solution prior to application [Stryker GmbH & Co. KG, 2008]. The 
question of BMP-7 binding to collagen and therewith retention at the site of 
application has not been clearly addressed. Goal of the present study was to load 
collagen/ceramic composites (CCCs) with defined amounts of BMP-7 under aseptic 
conditions. Therefore, quantification methods for BMP-7 and extraction strategies 
needed to be established to investigate whether protein integrity was affected by the 
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loading procedure. The BMP-7 enriched CCCs were to be transferred to the Clinical 
Center of the University of Munich for further in vitro studies with BMP-2 
overexpressing human mesenchymal stem cells (hMSCs), as synergistic osteogenic 
effects were described for the combination of BMP-2 and BMP-7 [Buket Basmanav et 
al., 2008; Laflamme and Rouabhia, 2008]. 
4.2 Materials and Methods 
All water used was highly purified and deionized using a USF ELGA PURELAB Plus 
UV/UF water purifier (Ransbach-Baumbach, Germany). To obtain insoluble porcine 
collagen type I raw material, porcine-skin derived collagen-suspension was prepared 
according to Meyer et al. [2010] and freeze-dried (Christ Epsilon 2-6D®, Osterode am 
Harz, Germany). Biphasic calcium phosphate granules (BCP, 60 % Hydroxyapatite, 
40 % ß-Tricalcium-Phosphate, 0.8 – 1.6 mm) were provided from Medtronic Sofamor 
Danek Deggendorf GmbH (Deggendorf, Germany). Recombinant human bone 
morphogenetic protein 7 (BMP-7) was purchased from PromoKine GmbH 
(Heidelberg, Germany). Histidine, arginine, TRIS, polysorbate 20, bromophenol blue 
sodium salt, disodiumhydrogenphosphate-dihydrate, and potassiumdihydrogen-
phosphate were from Merck KGaA (Darmstadt, Germany), methanol and acetic acid 
from VWR International (Darmstadt, Germany), glutamic acid from Fluka Chemie AG 
(Buchs, Switzerland) and sodium azide from ACROS ORGANICS (Thermo Fisher 
Scientific, Morris Plains, NJ, USA). All other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and analytical grade. Buffer compositions are listed in 
Table 4-1. All buffers contained 0.02 % sodium azide for preservation and pH was 
adjusted with 1 N hydrochloric acid or 1 N sodium hydroxide (VWR International, 
Darmstadt, Germany). Unless stated otherwise, all buffers contained 0.005 % 
polysorbate 20. 
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Table 4-1: Buffer compositions. 
Substance Concentration Composition [g] 
Glycine buffer pH 4.0 
glycine 20 mM 0.1501 
purified water  ad 100 mL 
Histidine buffer pH 6.0 
L-histidine 20 mM 0.3104 
purified water  ad 100 mL 
TRIS buffer pH 8.0 
TRIS 20 mM 0.2423 
purified water  ad 100 mL 
Arg-Glu buffer pH 4.5 (SEC-buffer) 
L-arginine·HCl 0.4 M 8.43 
glutamic acid 5 mM 0.074 
purified water  ad 100 mL 
Arg-His buffer pH 6.5 
L-arginine·HCl 0.5 M 10.5330 
L-histidine 10 mM 0.1552 
purified water  ad 100 mL 
PBS buffer pH 7.4 
sodium chloride 137 mM 0.8 
potassium chloride 2.7 mM 0.02 
disodiumhydrogenphosphate 10 mM 0.144 
potassiumdihydrogenphosphate 1.76 mM 0.024 
purified water  ad 100 mL 
PBST buffer pH 7.4 
sodium chloride 137 mM 0.8 
potassium chloride 2.7 mM 0.02 
disodiumhydrogenphosphate 10 mM 0.144 
potassiumdihydrogenphosphate 1.76 mM 0.024 
polysorbate 20  0.1 
purified water  ad 100 mL 
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4.2.1 Manufacturing of collagen/ceramic composites 
CCCs were prepared by dispersing the collagen raw material in water (pH adjusted 
to 3.7 with concentrated acetic acid) at a concentration of 4 % (w/w). After swelling 
for 4 h, the dispersions were homogenized with an ESGE® immersion blender (Unold 
AG, Germany). Biphasic calcium phosphate granules (BCP, 60 % Hydroxyapatite & 
40 % ß-Tricalciumphosphate, 0.8 – 1.6 mm, 50 % (m/m) related to collagen 
dispersion) were homogeneously admixed to the collagen dispersion. Dispersion-
aliquots were distributed into custom-made poly(methyl methacrylate) wells (diameter 
9 mm, height 5 mm) and freeze dried according to the protocol described in Table 4-
2. Based on dry mass each CCC consisted of 11.1 mg of collagen and 138.9 mg of 
BCP. 
 
Table 4-2: Freeze-drying protocol of collagen/ceramic composites. 
Process phase Time [hh:mm] Temperature [°C] Vacuum [mbar] 
Loading 00:00 20 --- 
Freezing 00:30 -5 --- 
Freezing 00:30 -5 --- 
Freezing 01:40 -15 --- 
Freezing 00:20 -35 --- 
Freezing 00:30 -35 --- 
Primary drying 00:01 -15 1.03 
Primary drying 00:29 -15 1.03 
Primary drying 23:00 -15 1.03 
Secondary drying 00:01 20 0.1 
Secondary drying 00:29 20 0.1 
Secondary drying 14:00 20 0.1 
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4.2.2 Size exclusion chromatography (SEC) 
An Agilent Technologies 1100 series instrument (Agilent Technologies, Böblingen, 
Germany), comprising degasser (1100 series), isocratic pump (IsoPump, 1100 
series), autosampler, variable wavelength detector (VWD, 1100 series) and 
fluorescence detector (FLD, 1200 series) was used. For sample separation a 
TSK-Gel®G2000SWxl (7.8 mm x 30 cm, 5 µm particle size, TOSOH Bioscience 
GmbH, Stuttgart, Germany) with a guard column (TSK-Gel®SWxl Guard Column, 6 
mm x 4 cm, particle size 7 µm, TOSOH Bioscience GmbH, Stuttgart, Germany) was 
used. Isocratic elution with 0.4 M L-arginine·HCl/5 mM glutamic acid buffer pH 4.5 
containing 0.4 % SDS at a flow rate of 0.6 mL/min was applied. Samples were 
pipetted into polypropylene inserts (Agilent Technologies), which were stuck into 
HPLC vials. Injection volume was 100 µL. Wavelengths used were λ = 230 nm 
(VWD) and λex = 230 nm and λem = 330 nm (FLD), previously determined by 
performing multi-emission and multi-excitation scans. Data analysis was performed 
with Agilent ChemStation® software (Agilent Technologies). 
4.2.3 SDS-Page 
NuPAGE® 10 % Bis-Tris gels and the protein standard Mark12 (Invitrogen, 
Carlsbad, USA) were used for electrophoresis. All samples were diluted 1:1 with 
sample buffer (25 ml Tris 1 M, 0.4 g SDS, 0.23 ml glycerin (87 %) and 1 ml 
bromophenol blue (0.1 %) made up to 100 mL with water, adjusted to pH 6.8 with 1 N 
HCl) and heated to 95 °C for 20 min. 20 µL of the samples were then applied to the 
gels and electrophoresis was run at 30 mA for 1.5 h. For protein visualization, the 
gels were stained with the silver staining kit SilverXpress® (Invitrogen, Carlsbad, 
USA).  
4.2.4 Western blot analysis 
Proteins were separated by SDS-Page (see 4.2.3). A prestained RTU protein ladder 
from PromoKine GmbH (Heidelberg, Germany) was used as standard. Samples were 
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transferred onto nitrocellulose membranes (Invitrogen) using an XCell II™ Blot 
Module (Invitrogen). All incubation steps were carried out at RT on an orbital shaker 
(Titramax 101, Heidolph Instruments GmbH, Schwabach, Germany) at 150 RPM 
unless otherwise stated. After washing with PBS-buffer, the membranes were 
blocked with 0.2 % Super-block (PromoKine GmbH) in PBST-buffer for 60 min. After 
washing with PBS-buffer, a rabbit polyclonal anti-BMP-7 antibody (0.2 µg/mL, 
overnight incubation at 2 - 8 °C) from PromoKine GmbH was used as primary 
antibody. After washing four times with PBST-buffer, PF-670 antibody conjugate goat 
anti-rabbit (PromoKine GmbH) was used for detection (1:2,000, 2 h incubation). After 
washing four times with PBST and three times with PBS-buffer, fluorescence 
intensity signals (k counts) were analyzed. Therefore, identical choice boxes were 
manually distributed to the respective signals and signal intensity was automatically 
determined using the Odyssey® imaging system (LI-COR Biosciences, Lincoln, USA).  
4.2.5 RhBMP-7 loading of collagen/ceramic composites 
For incorporation of rhBMP-7 into CCCs 10 µg of the lyophilized protein were 
reconstituted in different volumes (350 µL for SDS-Page analysis, 1050 µL for 
Western blot analysis) of glycine buffer pH 4.0 containing 0.005 % polysorbate 20. 
105 µL of rhBMP-7 were pipetted directly onto the scaffolds. After 5 min incubation at 
RT, 105 µL of a second buffer (histidine pH 6, TRIS pH 8, or TRIS pH 10) were 
added and the system incubated for 30 min. The liquids were loaded dropwise onto 
the center of the scaffold surface to ensure complete soaking into the composite 
material and to avoid protein loss due to adsorption to the surface of the eppendorf 
cups. To evaluate the incorporation efficiency a hole was pierced into the bottom of 
the eppendorf cups by means of a cannula (Terumo Neolus, 20G x 1 1/2, 0.9 x 40 
mm, Terumo Europe N.V., Leuven, Belgium). The caps were stuck into intact 
eppendorf cups and centrifuged for 10 min at 14000 rpm (Sigma 1-15, Christ GmbH, 
Osterode am Harz, Germany). Aliquots of the centrifugate in the lower eppendorf 
cups were analyzed by SDS-PAGE. The procedure is visualized in Figure 4-1. 
Negative controls (n=4) without rhBMP-7 were prepared accordingly and pH values 
were measured using a MP220 pH Meter (Mettler Toledo GmbH, Giessen, 
Germany). 
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Figure 4-1: Scheme for rhBMP-7 loading of collagen/ceramic composites. 
 
4.2.6 Aseptic manufacturing of rhBMP-7 loaded collagen/ceramic composites 
for cell culture testing 
All manufacturing steps were carried out under a HERAsafe® HS laminar flow box 
(Thermo Scientific, Massachusetts, USA). RhBMP-7 was diluted in glycine buffer pH 
4.0 at 0.2 mg/mL and sterile-filtered by means of a Millex®-GV PVDF filter (Millipore, 
Billerica, USA) with a pore size of 0.22 µm. Loss upon filtration was determined by 
Western blot analysis (see 4.2.4) and aliquots were deep frozen at -80 °C until further 
use. CCCs, manufactured according to 4.2.1 were fully soaked with 96 % ethanol. 
After evaporation of the ethanol, the CCCs were loaded each with 1 µg of rhBMP-7 
according to protocol 4.2.5 with TRIS buffer pH 8.0 as second buffer and directly 
transferred to Ph.D. cand. Ms. Uta Leicht for cell culture testing at the Clinical Center 
of the University of Munich. 
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4.2.7 Extraction of rhBMP-7 from collagen/ceramic composites and evaluation 
of binding behavior 
Either CCCs (see 4.2.1) or the respective components (11.1 mg of collagen or 
138.9 mg of BCP) or eppendorf cups without scaffolds were loaded with rhBMP-7 
(n=5) according to protocol 4.2.5 with TRIS buffer pH 8.0 as second buffer. In order 
to extract rhBMP-7, 1 mL of either HCl (pH 1) or Arg/His buffer (pH 6.5) were added 
and incubated on an orbital shaker (30 min, 400 rpm, Heidolph Titramax 101). A hole 
was pierced into the bottom of the eppendorf cups by means of a cannula (Terumo 
Neolus, 20G x 1 1/2, 0.9 x 40 mm). The caps were stuck into intact eppendorf cups 
and centrifuged for 10 min at 14,000 rpm (Sigma 1-15). Aliquots of the centrifugates 
were analyzed by Western blot (see 4.2.4). For statistical analysis Student’s t-test 
was used. 
4.3 Results and Discussion 
4.3.1 Incorporation of rhBMP-7 into collagen/ceramic composites 
In previous studies, besides successful outcome regarding osteogenic effects, little 
attention has been paid to the question, whether BMPs are in fact incorporated into 
the carrier materials. This concerns both combinations of rhBMP-7 with collagen and 
calcium phosphate [Cook et al., 1995; Gao et al., 1996]. Aim of our studies was to 
develop a defined loading procedure, enabling to quantitatively incorporate rhBMP-7 
into CCCs, while minimizing protein alteration. RhBMP-7 is used in a formulation 
buffer pH 4.0. Previous studies demonstrated that a pH shift from 5 to 7 leads to 
increased incorporation efficiency of rhBMP-2 into absorbable collagen sponges 
[Friess et al., 1999; Geiger et al., 2003]. The isoelectric point of the collagen used in 
our studies was 7.8 and the isoelectric point of rhBMP-7 was calculated to be 8.2. 
Consequently, increasing the pH in the course of the incorporation procedure was 
considered to be a promising way to decrease electrostatic repulsion between the 
two proteins and thereby to obtain higher incorporation efficiency. But it has also 
been shown that increasing the pH above 6.5 results in a decreased solubility of 
rhBMP-2 [Friess et al., 1999; Geiger, 2001] and a shift towards the isoelectric point 
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induced aggregation of rhBMP-2 [Luca et al., 2010]. Therefore, the desired pH, to 
combine efficient protein loading with a low protein alteration and precipitation was 
expected to be in the range between 4.0 and 8.2. The pH values resulting after 
loading procedures with different buffer combinations without rhBMP-7 are shown in 
Table 4-3. 
 
Table 4-3: Buffer combinations and resulting pH values measured after placebo 
loading CCCs (n=4). 
Buffer combinations pH 
glycine buffer pH 4 + histidine buffer pH 6 6.04 ± 0.05 
glycine buffer pH 4 + TRIS buffer pH 8 6.64 ± 0.21 
glycine buffer pH 4 + TRIS buffer pH 10 7.60 ± 0.18 
 
All tested loading buffer combinations rendered pH values within the desired range 
and were therefore further evaluated. Figure 4-2 exemplarily shows the silver stained 
SDS-Page analysis of the centrifuge effluent after loading rhBMP-7 onto 
collagen/ceramic scaffolds by using glycine buffer pH 4 and histidine buffer pH 6 and 
after extraction with Arg/His buffer pH 6.5. 
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Figure 4-2: SDS-Page of centrifugates and extracts after incorporating 143 ng 
rhBMP-7 into CCCs (glycin buffer pH 4 & histidine buffer pH 6; extraction with 
Arg/His buffer pH 6.5): Lanes (from the left): 1: Marker; 2: centrifugate blank; 3: 
centrifugate verum; 4: extract blank; 5: extract verum; 6: Diluted centrifugate verum 
(1:4.8); 7: 83.6 ng rhBMP-7; 8: 8.36 ng rhBMP-7. 
 
Due to the low quantity of 3 µg of rhBMP-7 loaded onto the scaffolds, compared to 
the 11.1 mg of collagen present in the composites, the rhBMP-7 bands are covered 
by collagen fragments in the silver stained SDS-Page analysis. Nevertheless, a semi-
quantitative assumption can be postulated: no signal with a comparable intensity to 
lane 7 representing 83.6 ng of rhBMP-7 is detectable, neither in the incorporation 
sample (lane 3) nor in the extraction sample (lane 5), indicating that a high amount of 
rhBMP-7 is bound to the CCC which could not be quantitatively removed. 
Incorporation at pH 6.6 and 7.6 led to comparable results, whereas incorporation 
without raising the pH led to incomplete binding efficiency (data not shown). Shifting 
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the pH towards higher values is therefore an effective method to increase the binding 
efficiency of rhBMP-7 to CCCs. However, a rhBMP-7 quantification method was still 
required and therefore SEC and Western blot analysis were further evaluated. 
4.3.2 Quantification of rhBMP-7 via SEC 
Literature is available describing the quantification of rhBMP-2 via SEC [Geiger, 
2001]. BMP-2 is a 32 kDa protein with an isoelectric point (IEP) of 8.2 [Geiger, 2001; 
Luca et al., 2010]. The molecular weight of BMP-7 is reported to be 25 - 40 kDa, 
depending on the grade of glycosylation, and its IEP can be calculated based on its 
amino acid sequence to be 8.2 [Griffith et al., 1996; PromoCell, 2011]. Due to the 
similarities beween BMP-2 and BMP-7, SEC column type, injection volume, elution 
buffer, and flow rate were adapted from Geiger [2001]. To obtain ideal wavelength 
settings, multi-emission and multi-excitation scans were performed, revealing a 
minimized signal to noise ratio at λ = 230 nm (for UV-detection) and an excitation 
wavelength of λex = 230 nm and detection at λem = 330 nm (for fluorescence 
detection). RhBMP-7 concentrations of 0.05 - 10 µg/mL in glycine buffer pH 4.0 were 
analyzed. To prevent protein adsorption to surfaces, 0.4 % sodium dodecyl sulfate 
(SDS) was added, which is above the critical micelle concentration for SDS in water, 
reported to be 0.23 % [Fuguet et al., 2005]. BMP-7 was eluted at a retention time of 
11.3 min and peak heights were used for calibration (see Figure 4-3). Linearity was 
fully given between 0.1 and 10 µg/mL and the limit of quantification was 0.25 µg/mL. 
However, the excessive presence of collagen interfered with the detection method 
despite the low aromatic amino acid content of collagen, responsible for the 
fluorescence signal. Consequently the method could not be used for the 
quantification of rhBMP-7 in combination with the CCCs (data not shown). 
Furthermore, the method was not feasible for a release testing, as a release of 
100 % would typically result in a maximum concentration of 0.83 µg/mL when using 
1 mL release medium (see 4.2.7).  
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Figure 4-3: Calibration curve of rhBMP-7 (n=2, glycine buffer pH 4.0, 0.4 % SDS, 
fluorescence detection signal: λex = 230 nm, λem = 330). 
 
4.3.3 Quantification of rhBMP-7 via Western blot 
A calibration curve was prepared diluting rhBMP-7 in glycine buffer pH 4.0 and 
performing a Western blot analysis (see 4.2.4) with quantities ranging from 1 - 40 ng. 
Figure 4-4 shows an exemplary image of the quantitative rhBMP-7 Western blot and 
the respective calibration curve is depicted in Figure 4-5. 
 
 
Figure 4-4: rhBMP-7 Western blot with selection boxes for automatic intensity 
calculation. 
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Figure 4-5: Calibration curve of a quantitative rhBMP-7 Western blot analysis. 
 
Numerous Western blot analyses of rhBMP-7 were performed to select the finally 
ideal conditions regarding signal-to-noise ratio and correlation coefficient (see 4.2.4). 
The sensitivity was increased by a factor of ~10 compared to SEC (see 4.3.2). 
Furthermore, the assay was not affected by the presence of collagen compared to 
SDS-Page (see 4.3.1). Consequently, the developed Western blot analysis was 
decided to be the method of choice for further analysis and quantification of rhBMP-
7. The combination of different growth factors showed beneficial results regarding 
bone regeneration [Zhang et al., 2009]. Heterodimers of BMP-2/7, BMP-2/6, and 
BMP-4/7 were found to promote increased bone formation in vivo compared to the 
effects of the respective homodimers [Aono et al., 1995; Israel et al., 1996]. The 
combination of BMP-2 and BMP-7 homodimers is superior regarding osteogenic 
differentiation compared to the isolated effects of the two bone morphogenetic 
proteins [Buket Basmanav et al., 2008; Laflamme and Rouabhia, 2008]. Among the 
“ForZebRA”-cooperation the combination of BMP-2 overexpressing hMSCs seeded 
on rhBMP-7 loaded CCCs was to be evaluated. Therefore, an aseptic manufacturing 
of the rhBMP-7 loaded scaffold needed to be developed (see 4.2.6) including sterile 
filtration of the rhBMP-7 solution. As rhBMP-7 has a high tendency of surface 
adsorption a substantial loss of protein was expected. However, quantitative Western 
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blot analysis showed that after sterile filtration of the rhBMP-7 solution with a PVDF 
filter 101.8 ± 4.2 % protein were recovered. The aseptically manufactured rhBMP-7 
loaded CCCs were transferred to Ph.D. cand. Ms. Uta Leicht for cell culture testing at 
the Clinical Center of the University of Munich. 
4.3.4 Extraction of rhBMP-7 from collagen/ceramic composites and evaluation 
of the binding behavior 
Aim of the setup was to extract rhBMP-7 from the previously loaded scaffolds and to 
gain insight into its integrity. As the increase in pH was responsible for high binding to 
the carrier material (see 4.3.1), HCl solution pH 1 was chosen for extraction to 
inverse the binding procedure. Arg/His buffer pH 6.5 was additionally chosen, as this 
buffer has previously been described as a promising extraction buffer for rhBMP-2 
from CCCs [Geiger, 2001]. High arginine concentrations (0.5 M) were shown to even 
completely suppress adsorption of BMP-2 [Duggirala et al., 1996]. Figure 4-6 
exemplarily shows a Western blot analysis for rhBMP-7 recovery. The extracted 
rhBMP-7 fractions (lanes 5-12) showed no signs of degradation or aggregation 
compared to the native rhBMP-7, used for calibration (lanes 2-4).  
 
 
Figure 4-6: rhBMP-7 Western blot; Lanes (from the left): 1: Marker; 2-4: calibration; 5: 
Blank HCl; 6: Blank Arg/His; 7: Collagen HCl; 8: Collagen Arg/His; 9: BCP HCl; 10: 
BCP Arg/His; 11: CCC HCl; 12: CCC Arg/His. 
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Figure 4-7: rhBMP-7 recovery determined by quantitative Western blot analysis 
 
Figure 4-7 shows the recovery of rhBMP-7 from collagen, BCP, and the CCC. The 
recovery from collagen showed lower recovery for Arg/His with 30.7 ± 11.6 % 
compared to 48.9 ± 5.2 % for HCl (p < 0.05). In contrast, Arg/His was much more 
effective extracting 71.6 ± 26.8 % compared to HCl extracting 14.0 ± 13.4 % of 
rhBMP-7 from BCP granules (p < 0.05). The lowest rhBMP-7 fractions were 
recovered from CCCs, 32.7 ± 12.7 % with Arg/His and 10.2 ± 5.1 % with HCl. The 
total rhBMP-7 amount extracted from CCCs with both extraction methods was lower 
compared to BCP and significantly lower compared to collagen (p < 0.05). Thus, the 
CCCs as a combination of collagen and BCP exhibit a synergistic binding capacity 
for rhBMP-7 and adsorption is the mechanism underlying the high incorporation 
efficiency [Luginbuehl et al., 2004]. We expect the developed scaffolds to exhibit high 
retention of rhBMP-7 at the site of application as Geiger proved higher retention of 
rhBMP-2 by the use of CCCs [2001]. The scaffolds are promising candidates for the 
upcoming in vitro studies at the Clinical Center of the University of Munich as 
sustained release of bone morphogenetic proteins is considered to be ideal for bone 
regeneration [Bessa et al., 2008]. 
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4.4 Conclusion 
Goal of the present study was to aseptically manufacture rhBMP-7 loaded 
collagen/ceramic composites, while minimizing protein alteration. Applying a second 
buffer with a higher pH to the rhBMP-7 enriched collagen/ceramic composite, 
causing a shift towards the isoelectric point of rhBMP-7, was proven to be the 
method of choice to obtain high incorporation efficiency. Detecting rhBMP-7 with the 
developed SEC method interfered with the excessive presence of collagen. The 
established, specific immunologic detection via Western blot analysis was shown to 
be insusceptible to collagen artifacts and ~10 times more sensitive for rhBMP-7 
compared to SEC. The quantitative Western blot enabled to investigate the loss upon 
sterile filtration of rhBMP-7, necessary for aseptic manufacturing. A PVDF filter was 
proven not to decrease the yield of rhBMP-7 after filtration. Upon the extraction of 
rhBMP-7 from the collagen/ceramic composites by lowering the pH or applying 
Arg/His buffer, no signs of degradation were detectable by Western blot. Arg/His 
buffer pH 6.5 was the most effective tool, extracting 32.7 ± 12.7 % of the previously 
incorporated rhBMP-7. This overall low recovery highlights the strong retentive 
potential for rhBMP-7 of the carrier material. The combination of collagen and 
biphasic calcium phosphate showed a synergy in binding compared to the isolated 
carrier materials. Therefore, we conclude that the rhBMP-7 loaded collagen/ceramic 
composites developed in this study are promising candidates for further in vitro and 
in vivo studies, which will be conducted at the Clinical Center of the University of 
Munich. 
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5 Oxygen Generating Collagen/Ceramic Composites 
 
Abstract 
Aim of the present study was to develop a formulation providing sustained oxygen-
release in order to achieve elevated oxygen levels in a collagen/ceramic composite 
scaffold for several days. This can help to maintain cell viability in larger tissue 
engineering constructs, where oxygen diffusion limits cell survival. The oxygen was 
provided by granulated materials based on calcium peroxide. A bigger particle size 
enabled to reduce the initial burst, but did not provide sustained oxygen release. 
Neither CaO2 formulations containing hard fat nor poly(lactic-co-glycolic acid) 
rendered the desired release profile. Granulation with ethyl cellulose (EC) led to 
reduced initial burst and to significantly elevated oxygen levels throughout the 
investigation time period of 72 h. This lead candidate was incorporated into 
collagen/ceramic composite scaffolds and similar oxygen release behavior was 
found. Catalase added to the release medium or embedded into the freeze-dried 
ready-to-use oxygen generating collagen/ceramic composites allowed to keep 
hydrogen peroxide levels at a minimum without influencing the oxygen release. 
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5.1 Introduction 
In the field of tissue engineering it has been shown that adequate filling materials 
facilitate tissue regeneration [Groeneveld et al., 1999]. Scaffolds intended for bone 
regeneration are usually either cultivated with cells in vitro [Ge et al., 2009b] or 
implanted without prior cell seeding [Ge et al., 2009a]. An ex vivo cell seeding 
followed by implantation can lead to increased hypoxia inside the scaffolds due to 
inadequate perfusion [Liu et al., 2009]. However, homogeneous oxygen distribution is 
of crucial importance for the quality of the engineered tissue [Volkmer et al., 2008]. In 
mammalians, cells are supplied with the essential oxygen by diffusion from 
surrounding blood vessels. A distance from the blood vessels exceeding 100 – 
200 µm can be enough that adequate oxygen supply is no longer ensured [Carmeliet 
and Jain, 2000]. Several approaches have been evaluated to overcome this problem 
in larger implants, like improved scaffold porosity, incorporation of angiogenic signals 
(e.g. VEGF) directly or via genetically engineered cells, seeding of endothelial cells, 
prevascularization prior to seeding, or increased oxygen capacity of the used cell 
culture medium [Karande et al., 2004; Nomi et al., 2002]. Another approach is the 
use of oxygen generating biomaterials [Oh et al., 2009]. Oxygen generating 
biomaterials were shown to extend cell viability under hypoxic conditions and to 
prevent the necrosis of unvascularized tissue in vivo for several days [Harrison et al., 
2007]. The material of interest used in the present study is a collagen/ceramic 
composite (CCC). Numerous collagen and ceramic based materials have been used 
for tissue engineering and cells have been successfully cultivated on mineralized 
collagen [Cunniffe and O’Brien, 2011; Gelinsky et al., 2008; Shepherd and Best, 
2011]. Goal of our study was to develop a sustained release-formulation for the in-
situ oxygen generation and its incorporation into CCCs to bridge the timeframe 
between implantation and neovascularization of the constructs. 
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5.2 Materials and Methods 
All water used was highly purified and deionized using a USF ELGA PURELAB Plus 
UV/UF water purifier (Ransbach-Baumbach, Germany). Hard fat qualities Witepsol 
E75, E85, and W45 were from CONDEA (Witten, Germany). Poly(lactic-co-glycolic 
acid) PLGA 50:50 Resomer RG 503 (RG 503) or RG 502H (RG 502H) were from 
Boehringer Ingelheim (Ingelheim, Germany). Calcium peroxide (CaO2) and catalase 
from bovine liver were from Sigma-Aldrich (St. Louis, MO, USA). Ethyl cellulose NF 
(EC) was from Dow Chemical Company (Midland, MI, USA). Disodiumhydrogen-
phosphate-dihydrate, potassiumdihydrogenphosphate of analytical grade and 
colorimetric peroxide test strips were from Merck KGaA (Darmstadt, Germany). 
Sodium azide was from ACROS ORGANICS (Thermo Fisher Scientific, Morris 
Plains, NJ, USA). Biphasic calcium phosphate granules (BCP, 60 % Hydroxyapatite, 
40 % ß-Tricalcium-Phosphate, 0.8 – 1.6 mm) were provided from Medtronic Sofamor 
Danek (Deggendorf, Germany). All other chemicals were purchased from Sigma-
Aldrich and of analytical grade. Porcine-skin derived collagen-suspension was 
prepared according to Meyer et al. [2010] and freeze-dried (Christ Epsilon 2-6D, 
Osterode am Harz, Germany) to obtain insoluble porcine collagen type I raw 
material. 
5.2.1 Preparation of CaO2 granules by compacting and grinding 
CaO2 was compacted using a hydraulic compactor (Maassen, Reutlingen, Germany) 
with a pressure of 1 t. The pellet was grinded by means of mortar and pestle. The 
particle size fraction of interest (90 - 355 µm) was obtained by sieving.  
5.2.2 Preparation of CaO2/lipid composite granules by compacting and 
grinding 
Lipids of interest (see Table 5-1) were melted at 50 °C and CaO2 was 
homogeneously dispersed. After cooling to 22 °C the material was grinded using 
mortar and pestle. Sieving rendered the desired particle size fraction of 90 – 355 µm.  
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Table 5-1: Formulations of CaO2/lipid composite granules based on 100 g. 
Formulation E75 20% E75 30% E85 30% E85 50% W45 20% W45 30% 
CaO2 80 g 70 g 70 g 50 g 80 g 70 g 
Lipid 
component 
20 g 30 g 30 g 50 g 20 g 30 g 
5.2.3 Preparation of CaO2/PLGA composite granules by dissolving and grating 
RG 503 and RG 502H were dissolved in acetone and CaO2 was homogeneously 
dispersed (22 g of CaO2 per 78 g of PLGA). After acetone evaporation the material 
was grinded using a grater and sieved to obtain the 90 – 355 µm particle size 
fraction.  
5.2.4 Preparation of CaO2/ethylcellulose composite granules by dissolving 
and grating 
Ethyl cellulose (EC) was dissolved in ethanol at a concentration of 8 %. CaO2 with 
and without the addition of catalase was granulated by a step-wise addition of small 
portions of approx. 2 g ethanolic EC-solution (compositions see Table 5-2). The 
ethanol was evaporated and the material was grinded using a grater and sieved to 
obtain the 90 – 355 µm particle fraction. 
 
Table 5-2: Formulations of CaO2/ethyl cellullose composite granules based on 100 g. 
Formulation 30 % 
30 % EC + 
Catalase 
45 % 60 % 
CaO2 70 g 69.51 g 55 g 40 g 
Ethyl cellulose 30 g 29.79 g 45 g 60 g 
Catalase - 0.70 g - - 
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5.2.5 Manufacturing of oxygen generating collagen/ceramic composites 
CCCs were prepared by dispersing the collagen raw material in water (pH adjusted 
to 3.7 with concentrated acetic acid) at a concentration of 4 % (w/w). After swelling 
for 4 h, the dispersions were homogenized with an ESGE immersion blender 
(Unold, Germany). BCP granules (50 % (m/m) related to collagen dispersion) were 
homogeneously admixed to the collagen dispersion. Samples were prepared without 
further additives (CCC blank), with the addition of granulated CaO2 (see 5.2.1), 
CaO2/EC granules (see 5.2.4) with and without embedded catalase (formulations see 
Table 5-3).  
 
Table 5-3: Formulations of oxygen generating CCCs; calculation based on dry mass 
of 1 CCC. 
Formulation CCC blank CCC CaO2 CCC EC/CaO2 
CCC EC/CaO2 
Catalase 
Collagen 11.11 mg 11.04 mg 11.01 mg 11.00 mg 
BCP 138.89 mg 137.96 mg 137.57 mg 137.56 mg 
CaO2 - 1 mg 1 mg 1 mg 
Ethyl cellulose - - 0.43 mg 0.43 mg 
Catalase - - - 10 µg 
 
Dispersion-aliquots were distributed into custom-made poly(methyl methacrylate) 
wells (diameter 9 mm, height 5 mm) and freeze dried according to the following 
protocol (Table 5-4): 
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Table 5-4: Freeze-drying protocol of CCCs. 
Process phase Time [hh:mm] Temperature [°C] Vacuum [mbar] 
Loading 00:00 -40 --- 
Freezing 02:00 -40 --- 
Primary drying 00:01 -15 1.03 
Primary drying 00:29 -15 1.03 
Primary drying 23:00 -15 1.03 
Secondary drying 00:01 20 0.1 
Secondary drying 00:29 20 0.1 
Secondary drying 14:00 20 0.1 
5.2.6 Evaluation of oxygen release 
Samples of interest (n=3) were placed in 100 mL DURAN laboratory glass bottles 
containing 80 mL 250 mM phosphate buffer pH 7.4 (1 L contained 5.24 g potassium-
dihydrogenphosphate, 37.6 g disodiumhydrogenphosphate-dihydrate, and 0.2 g 
sodium azide). A hole was cut into the screw cap to hold the oxygen sensors 
(Needle-Type Housing Fiber-Optic Oxygen Microsensor, PreSens Precision Sensing, 
Regensburg, Germany). The sensors were placed in a central position inside the 
buffer (for oxygen generating granules) or directly inside the oxygen generating 
CCCs. The glass bottles were placed on a magnetic stirrer (300 RPM for oxygen 
generating granules, no magnetic stir bar for oxygen generating CCCs) in a chamber 
heated to 37 °C. Calibration of the sensors was performed with nitrogen (0 % 
oxygen) and pure 250 mM phosphate buffer pH 7.4 (100 % oxygen saturation). Due 
to software conversion, the release buffer being 100 % saturated with ambient 
oxygen is displayed as 20.9 % relative oxygen saturation. Oxygen generating CCCs 
were analyzed individually containing 1 mg CaO2 each, whereas CaO2 granules were 
tested at quantities reflecting 100 mg CaO2 each. The peroxide content was 
measured with colorimetric peroxide test strips after 72 h. 
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5.3 Results and Discussion 
5.3.1 CaO2 – influence of particle size on oxygen generation 
In presence of water, 1 mol of CaO2 generates 1 mol of hydrogen peroxide, which 
decomposes into ½ mol of O2 (Equation 5-1). The blanks depicted in Figure 5-1 show 
around 20.9 % relative oxygen saturation reflecting the characteristic oxygen content 
of the atmosphere. CaO2 containing samples resulted in a substantial increase in the 
oxygen content with a maximum reached after approx. 15 min and baseline levels in 
the open system allowing exchange with the atmosphere were reached after approx. 
12 - 24 h. The highest oxygen concentration was measured for the CaO2 powder 
(median size: 15 µm) after 0.25 h with 43.6 ± 0.8 %, whereas CaO2 with a particle 
size of 90 - 355 µm reached only 38.7 ± 1.3 % after 0.60 h (p < 0.01). CaO2 is poorly 
water soluble and consequently a slower hydrolysis with a reduced surface area and 
larger particle size corresponds with our observations [Bauer et al., 2006]. A high 
initial release can explain higher oxygen concentrations throughout the whole 
measurement time for the CaO2 powder (median size: 15 µm). A difference < 1 % to 
the blanks was reached after 27 h for the CaO2 powder (median size: 15 µm) and 
after 12 h for the 90 - 355 µm CaO2. Overall, the influence of the particle size on 
oxygen release behavior was lower as expected. Thus, the approach to generate a 
sustained release of oxygen by the use of CaO2 with a larger particle size was 
limited, as particles > 355 µm were regarded as inappropriate for the desired 
application. Hydrolysis of CaO2 resulted in the formation of calcium phosphate due to 
the presence of phosphate ions in the used buffer. 
 
 
Equation 5-1: Reaction of oxygen generation from CaO2. 
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Figure 5-1: Oxygen saturation of phosphate buffer in presence of CaO2 powder 
(median size: 15 µm) or compacted CaO2 with 90 - 355 µm particle size. 
5.3.2 Oxygen release from CaO2 containing composite granules 
5.3.2.1 Oxygen release from CaO2/lipid composite granules 
Lipids can be used to obtain implantable sustained release systems for 
pharmaceutical drugs [Wang, 1989]. Inflammatory response after implantation is not 
higher compared to commonly used PLGA based implants [Reithmeier et al., 2001]. 
To obtain a sustained release of oxygen, granules of CaO2 and different hard fat 
qualities (see Table 5-5) as lipid components were prepared and the release 
behavior was evaluated. Hard fat is commonly used as suppository base and 
releases the active pharmaceutical ingredient (API) upon melting [Gjellan and 
Graffner, 1994]. A lower melting point of the suppository base leads to faster 
disintegration and thus release [Hammouda et al., 1993]. The hydroxyl value, 
representing the availability of free hydroxyl groups, also influences the release of the 
API. Poorly water soluble APIs were shown to be released slower from bases with 
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higher hydroxyl values [Webster et al., 1998], whereas suppository bases with a high 
hydroxyl value provide faster release of hydrophilic APIs [Akala et al., 1991]. 
Therefore we expected the fastest release of the hydrophilic CaO2 for the 
composition with the highest hydroxyl value and the lowest melting point Witepsol® 
W45. Figure 5-2 shows the release profiles of the tested CaO2/lipid composite 
granules in comparison to CaO2 powder (median size: 15 µm) (see 5.3.1). 
 
Table 5-5: Overview of the used hard fat components, adapted from [Sasol GmbH, 
2007]. 
Hard Fat  Ascending melting point 
[°C] 
Hydroxyl value  
[mg KOH/g] 
Witepsol® E75 38 <15 
Witepsol® E85 42 - 44 5 - 15 
Witepsol® W45 33.5 - 35.5 40 - 50 
   
   
 
Figure 5-2: Oxygen saturation of phosphate buffer in presence of CaO2 powder 
(median size: 15 µm) or CaO2/lipid composite granules (90 - 355 µm). 
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Generally the observed differences between the compositions containing different 
Witepsol® types were lower as expected. Although E75 80/20 and E85 70/30 appear 
to generate slightly higher oxygen concentrations after approx. 6 h, these differences 
were not statistically significant (see Table 5-6). 
 
Table 5-6: Statistical analysis (t-test) of oxygen release after 6 h, 24 h, and highest 
oxygen release (cmax), displayed as (6h/24h/cmax). P-values > 0.05 are displayed as 
“not significant” (ns), others are rounded to the second decimal place. 
 cmax E75 8/2 E75 7/3 E85 7/3 E85 5/5 W45 8/2 W45 7/3 
CaO2 43.6 ns/ns/0.02 ns/ns/0.01 ns/ns/ns ns/ns/<0.01 ns/0.01/ns ns/ns/ns 
E75 8/2 40.2  ns/ns/ns ns/ns/ns ns/ns/<0.01 ns/ns/0.01 ns/ns/ns 
E75 7/3 38.1   ns/ns/ns ns/ns/<0.01 ns/ns/<0.01 ns/ns/ns 
E85 7/3 37.5    ns/ns/ns ns/ns/ns ns/ns/ns 
E85 5/5 28.4     ns/ns/<0.01 ns/ns/<0.01 
W45 8/2 45.1      ns/ns/ns 
W45 7/3 44.8       
 
The 50/50 composition of CaO2 with Witepsol® E85 showed the overall lowest burst 
release being significantly lower compared to the CaO2 powder (median size: 15 µm) 
and all other formulations, except E85 70/30 (see Table 5-6). It led to a reduction 
(p < 0.005) of the maximum oxygen concentration (cmax) to 28.4 ± 1.7 % after 1.5 h 
compared to 43.6 ± 0.8% after 0.25 h for CaO2 powder (median size: 15 µm). None 
of the tested formulations provided longer significantly elevated oxygen 
concentrations compared to CaO2 powder (median size: 15 µm). W45 80/20 provided 
a significantly decreased oxygen concentration after 24 h (see Table 5-6). 
5.3.2.2 Oxygen release from CaO2/PLGA composite granules 
PLGA based drug delivery systems are well established in marketed products 
providing sustained release of APIs, such as leuprorelin (Lupron Depot®, Enantone®, 
Trenantone®, Eligard®), goserelin (Zoladex®), triptorelin (Decapeptyl®), somatotropin 
(Nutropin Depot®), buserelin (Profact®), bromocriptine (Parlodel LP®), risperidon 
(Risperdal consta®), naltrexone (Vivitrol®), or minocyclin (Arestin®) [Álvarez et al., 
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2011; Sah and Lee, 2006; Schwach et al., 2003; Wischke and Schwendeman, 2008]. 
The mechanisms underlying drug release from PLGA based systems are drug 
diffusion, polymer degradation and erosion. Water influx leads to hydrolysis of the 
polymer and thereby degradation to oligomers and monomers leading to erosion of 
the matrix. For PLGA, typically bulk erosion occurs due to water influx being faster 
than hydrolysis [Göpferich, 1997; Langer and Peppas, 1983]. As an alternative to 
lipid matrix materials, we used PLGA to obtain sustained oxygen release from 
CaO2/PLGA composite granules. Harrison et al. generated PLGA films containing 
sodium percarbonate, exhibiting release of oxygen over 24 h. Their films enabled to 
prevent necrosis of unvascularized tissue for several days using a skin flap model in 
mice [2007]. Figure 5-3 shows the oxygen saturation levels of the buffer for the two 
investigated CaO2/PLGA composite granules compared to blank and CaO2 powder 
(median size: 15 µm).  
 
Figure 5-3: Oxygen saturation of phosphate buffer in presence of CaO2 powder 
(median size: 15 µm) or CaO2/PLGA composite granules (90 - 355 µm). 
 
The different CaO2/PLGA composite granules provided significantly higher cmax 
values compared to CaO2 powder (43.6 ± 0.8 %) (p < 0.05) but did not significantly 
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differ in cmax among each other (61.6 ± 4.8 % (RG 502H) vs. 55.0 ± 7.7 % (RG 503)). 
The CaO2/RG 503 composite granules provided a high initial burst release of oxygen 
followed by a drop below the oxygen level created by CaO2 powder (median size: 
15 µm). In contrast, the CaO2/RG 502H formulation appeared to exhibit a sustained 
high oxygen saturation level. It even provided oxygen levels elevated by 1 % after 
59 h and by 0.4 ± 0.1 % after 72 h (p < 0.05) compared to blanks. We expect this to 
result from the lower molecular weight and the free carboxylic end-groups of the RG 
502H. It has been shown that a reduced molecular mass [Park, 1994] and non-
esterified carboxylic end-groups [Göpferich, 1997] increase the degradation rate of 
PLGA polymers. Faster degradation is accompanied by acidic degradation products 
of PLGA leading to a decreased pH value inside the matrix [Mäder et al., 1996]. With 
regards to Equation 5-1, a pH decrease leads to faster hydrolysis rates of CaO2. We 
conclude that the RG 502H based formulation improves the solubility of the 
embedded CaO2. Nevertheless, a high initial burst release can go hand in hand with 
elevated hydrogen peroxide concentrations which are known to be unfavorable 
regarding cell survival [Lee et al., 2006]. Due to the high initial burst release of 
oxygen for the tested PLGA based systems those formulations were regarded as 
unfavorable for the desired application. 
5.3.2.3 Oxygen release from CaO2/ethyl cellulose composite granules 
As an alternative to lipid and PLGA based CaO2 systems, granules of CaO2 in 
combination with different amounts of ethyl cellulose were prepared and the release 
behavior was evaluated. Figure 5-4 shows the release profiles of the tested CaO2/EC 
composite granules in comparison to the CaO2 powder (median size: 15 µm). 
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Figure 5-4: Oxygen saturation of phosphate buffer in presence of CaO2 powder or 
CaO2/EC composite granules (90 - 355 µm). 
 
The combination of CaO2 with different amounts of ethyl cellulose led to a significant 
(p < 0.05) reduction of initial burst release to 35.7 ± 2.1 % and tmax was delayed to 
1.3 ± 0.1 h compared to CaO2 powder (0.25 h, 43.6 ± 0.8 %) and CaO2 with a particle 
size of 90 - 355 µm (0.6 h, 38.7 ± 1,3 %) (see 5.3.1). No significant difference in tmax, 
cmax, or in oxygen concentration was found among the formulations with different 
ethyl cellulose content throughout the whole investigation period. After 72 h the 
CaO2/EC systems generated a 1.0 ± 0.1 % higher oxygen level compared to the 
formulations without ethyl cellulose (p < 0.005) and 0.5 ± 0.1 % higher oxygen 
saturation compared to CaO2/RG 502H 22/78 (p < 0.05) (see 5.3.2.2). EC is 
frequently used to engineer oral sustained release formulations for hydrophilic drug 
substances either by direct compression or granulation. The release is mainly 
controlled by diffusion and partially by erosion of the matrix [Katikaneni et al., 1995; 
Reddy et al., 2003]. Rotstein et al. further found that EC-layers can function as a 
diffusive barrier for hydrogen peroxide [1992]. Therefore, we consider the EC 
formulation well suited for the desired purpose to design a sustained oxygen release 
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system from CaO2. The CaO2/EC 70/30 formulation delivered a reduced burst and a 
substantially extended timeframe of elevated oxygen levels, while it contained the 
lowest EC concentration tested and was therefore chosen to be incorporated into the 
CCCs. 
5.3.3 Oxygen release from oxygen generating collagen/ceramic composites 
and the effect of catalase 
Consequently, the oxygen concentration inside CCCs was evaluated in order to show 
whether the processing of the CaO2 into the composites affects the oxygen 
generation. The samples contained 1 mg of CaO2 each, either as pure CaO2 or as 
ethyl cellulose containing granules with a particle size of 90 - 355 µm. Catalase was 
either added to the buffer or directly embedded into the CaO2/EC 70/30 formulation 
(see 5.2.5). Catalase is used due to its ability to catalyze the decomposition of 
cytotoxic hydrogen peroxide into oxygen and water [Abdi et al., 2011; Oh et al., 
2009], what also raises the question whether it on the other hand side can affect the 
equilibrium of oxygen generation. Figure 5-5 shows the oxygen release from CCCs 
with embedded CaO2 granules (90 - 355 µm) with and without the addition of 
catalase. The oxygen release from CCCs containing CaO2/EC formulations with and 
without embedded catalase and catalase in the release buffer is depicted in Figure 5-
6. The oxygen release profiles were not affected by the presence of catalase in any 
form. Each mg of CaO2 (equivalent to 0.014 mmol) generates 0.014 mmol of 
hydrogen peroxide (see Equation 5-1). Cytotoxicity of H2O2 starts at 0.3 mmol/L [Lee 
et al., 2006]. Assuming that CaO2 would completely and instantly generate H2O2 
without further decomposition into H2O and O2 a volume of 46.7 mL would be 
sufficient to keep the concentration of H2O2 below the cytotoxic 0.3 mmol/L level 
(equivalent to 10.2 mg/L H2O2). Also Harrison et al. showed that although even 
3.57 mmol (equivalent to 121.4 mg) of hydrogen peroxide were generated 
intermediately in close vicinity to an area of 10 x 20 mm, oxygen generating 
constructs prevented necrosis in vivo [2007]. Therefore, it can be assumed that the 
H2O2 concentration generated in vivo by our constructs will be uncritical. In our 
studies the hydrogen peroxide content determined with colorimetric test strips after 
72 h of release was 2 mg/L (0.1 mmol/L) for the samples without catalase, whereas 
in the catalase containing samples hydrogen peroxide content was below 0.5 mg/L 
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(0.025 mmol/L). The amount of catalase added or incorporated should theoretically 
be able to decompose the generated H2O2 to H2O and O2 within 14 min at pH 7 and 
25 °C [Sigma-Aldrich, 2011]. Therefore, it is remarkable that H2O2 is still detectable 
even after 72 h. Whether catalase was added to the release buffer or directly 
incorporated into the CaO2/EC granules did not affect the hydrogen peroxide 
contents. 
 
Figure 5-5: Oxygen saturation measured inside CCCs with CaO2 (90 - 355 µm) with 
or without the addition of catalase to the release medium (phosphate buffer). 
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Figure 5-6: Oxygen saturation measured inside the CCCs containing CaO2 in form of 
CaO2/EC formulations with or without the addition of catalase to the release buffer 
and catalase incorporated into the CCCs. 
5.3.4 Oxygen release from CaO2/ethyl cellulose composite granules 
containing collagen/ceramic composites 
Figure 5-7 exemplarily shows a comparison of the oxygen generation profiles of 
collagen ceramic composites with either CaO2 or CaO2/EC 70/30 incorporated. No 
significant influence of the processing into the final composites on the initial burst 
release of oxygen was detected. Comparing all tested CaO2 containing CCCs with all 
CaO2/EC containing CCCs, oxygen saturation of the CaO2 containing samples was 
not significantly higher compared to blanks after 36 h, whereas the oxygen 
concentration for the samples containing CaO2/EC formulations was 0.9 ± 0.6 % 
higher compared to the system with CaO2 (90 - 355 µm) embedded without EC 
(p < 0.005) even after 72 h of release. The developed formulation combining CaO2 
with ethyl cellulose is therefore a successful tool for the manufacturing of CCCs 
providing elevated oxygen levels over three days. The further incorporation of 
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catalase enabled to significantly reduce the concentration of hydrogen peroxide, 
measured after 72 h from 1.5 ± 0.5 mg/L to 0.375 ± 0.29 mg/L (p < 0.05) and 
therewith far below the concentration of 10.2 mg/L considered to be cytotoxic [Lee et 
al., 2006]. It is again remarkable that H2O2 is still detectable after 72 h. As one cannot 
exclude that higher H2O2 concentrations occur during the release period, following in 
vitro studies should find ideal quantities of CaO2 and catalase for the desired 
application site. We consider the developed scaffolds to be a promising biomaterial 
for larger defect sites, where adequate oxygen supply is a critical factor for the quality 
of the engineered tissue [Volkmer et al., 2008]. 
 
Figure 5-7: Oxygen saturation measured inside the CCCs enriched with either CaO2 
granules (90 - 355 µm) or CaO2/ethyl cellulose 70/30 granules (90 - 355 µm). 
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5.4 Conclusion 
In the present study we developed a calcium peroxide formulation for sustained 
oxygen generation in a collagen/ceramic composite. The oxygen generation from 
calcium peroxide was affected by the particle size as smaller particles resulted in 
faster oxygen generation. As dissolution of the particles is limited, the effect is in 
accordance with the Noyes-Whitney equation. The release testing of composite 
granules with calcium peroxide and different hard fat qualities demonstrated no 
significant difference to pure calcium peroxide, except for the formulation containing 
50 % hard fat, where the initial burst was reduced. The combination of calcium 
peroxide with different PLGA qualities showed that the more hydrophilic RG 502H 
even acts as a solubility enhancer creating high oxygen levels. The granulation of 
calcium peroxide with ethanolic ethyl cellulose solution rendered composite granules 
generating elevated oxygen levels by 1 ± 0.1 % compared to compressed CaO2 
without EC after 72 h of release (p < 0.005), while the initial burst was reduced. The 
incorporation of this lead candidate into collagen/ceramic composites followed by 
release testing showed comparable results increasing the oxygen levels by 
0.9 ± 0.6 % after 72 h of release (p < 0.005). Additionally incorporated catalase 
significantly reduced the content of cytotoxic hydrogen peroxide (p < 0.05) without 
having an influence on oxygen generation. Therefore, the developed formulation for 
the sustained release of oxygen and its combination with catalase, to ensure low 
hydrogen peroxide concentrations, appears to be promising for further in vitro and in 
vivo studies. It allows the manufacturing of larger tissue engineering constructs, 
where a lack of oxygen inside the scaffolds limits cell survival. 
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6  Final summary 
The focus of this thesis was on the development of improved biomaterials for 
regenerative medicine. At first, an in-situ hardening system based on PLGA was 
developed. The formulations further contained a water miscible organic solvent, an 
inorganic component (α-TCP), and a pore forming agent (NaCMC). After injection 
into an aqueous surrounding, the occurring solvent exchange process led to the 
precipitation of PLGA and to the formation of a solid scaffold, exhibiting high porosity 
while maintaining good mechanical resistance to uniaxial compression. To combine 
the osteoconductive scaffold with an osteogenic working principle, the formulations 
were tested for cell compatibility in order to find a formulation enabling to directly 
incorporate cells. Therefore, the formulation recipes were optimized regarding their 
initial content of aqueous medium without influencing the properties of the resulting 
scaffold while the organic solvents were tested for cell compatibility. The most 
promising formulations were subsequently enriched with SCP-1 cells. During the 
solvent exchange process after administration into cell culture medium, cells were 
not able to attach to the scaffold matrix and were therefore washed out. Cultivating 
the cells on α-TCP before preparing the in-situ hardening formulation enabled their 
successful incorporation into the scaffold after solvent exchange. However, cell 
viability could not be maintained. Nevertheless, a putty-like system exhibiting high 
porosity and good mechanical stability was successfully developed. 
In a different approach insoluble porcine collagen type I was treated with 
Streptomyces mobaraensis derived transglutaminase (mTG). Neither increased 
denaturation temperature nor reduced enzymatic degradation rates were observed, 
but an increased tensile strength was obtained. A Western blot analysis showed, 
although numerous washing steps to remove mTG were performed, that substantial 
mTG amounts remained non-covalently associated with the collagen material. To 
quantify the mTG amount in the washing fluids as well as in the modified collagen 
materials, an ELISA was developed. The analyses demonstrated that approximately 
40 % of the initially applied mTG were still associated with the collagen material. A 
further reduction of mTG-residuals was achieved by a treatment with guanidinium 
chloride. Dialysis at pH 2 and pH 12 enabled a complete removal of mTG, but 
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comprised the drawback of amide bond hydrolysis and thereby decreased tensile 
strength.  
Subsequently, the aseptic manufacturing of rhBMP-7 loaded collagen/ceramic 
composites was addressed. While other analytical methods comprise the drawback 
of poor specificity, Western blot analysis was our method of choice to detect and 
quantify rhBMP-7. After sterile filtration through a PVDF-filter, rhBMP-7 was 
completely recovered. Loading experiments showed that a pH shift towards the 
isoelectric point resulted in high incorporation efficiency, while the combination of 
collagen and biphasic calcium phosphate granules exhibited synergistic binding 
properties for rhBMP-7. Amongst the different extraction strategies the use of Arg/His 
buffer pH 6.5 was most effective recovering 32.7 ± 12.7 % of the previously loaded 
rhBMP-7. No signs of degradation were detected for the extracted rhBMP-7. 
Finally, several excipients were tested for their potential to allow the manufacturing of 
a formulation providing sustained oxygen release from calcium peroxide. The use of 
different hard fat types only led to a reduced initial burst for a formulation containing 
50 % hard fat. Combining calcium peroxide with PLGA resulted in even higher 
oxygen release compared to isolated calcium peroxide. Granules made of calcium 
peroxide and ethyl cellulose allowed to generate formulations providing sustained 
oxygen release and to reduce the initial burst. The calcium peroxide/ethyl cellulose 
granules were subsequently incorporated into collagen/ceramic composites and 
release testing showed oxygen levels which were significantly increased by 
0.9 ± 0.6 % after 72 h of incubation (p < 0.005). The additional incorporation of 
catalase reduced the amount of cytotoxic hydrogen peroxide. We consider the 
developed oxygen generating collagen/ceramic composites to be a promising 
biomaterial for larger tissue engineering constructs, where oxygen availability is a 
limiting factor. 
Thus, these developments of advanced biomaterials for bone tissue engineering 
might overall contribute to regenerative medicine to meet the requirements of an 
aging society.  
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API active pharmaceutical ingredient 
Arg arginine 
AUC area under the curve 
BCP biphasic calcium phosphate 
BMP bone morphogenetic protein 
BSA bovine serum albumine 
CAD computer aided design 
CaO2 calcium peroxide 
CCC collagen/ceramic composite 
cmax maximum concentration 
DMSO dimethyl sulfoxide 
EC ethyl cellulose 
ECM extracellular matrix 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide 
ELISA enzyme-linked immunosorbent assay 
ESC embryonal stem cell 
FDA fluoresceindiacetate 
FDA U. S. Food and Drug Administration 
Glu glutamine 
Gly glycine 
gTG guinea pig liver transglutaminase 
H2O water 
H2O2 hydrogen peroxide 
H2SO4 sulfuric acid 
HA hydoxyapatite 
HCl hydrochloric acid 
His  histidine 
HMDC hexamethylene diisocyanate 
IEP isoelectric point 
IgG immunoglobulin G 
iPSC induced pluripotent stem cell 
IsHS in-situ hardening system 
  List of Abbreviations 
LD50 lethal dose (50 %) 
MSC mesenchymal stem cell 
mTG microbial transglutaminase 
N normal 
NaCMC sodium carboxymethyl-cellulose 
NaOH sodium hydroxide 
NMP 1-methyl-2-pyrollidone 
O2 oxygen 
PBS phosphate buffered saline 
PBST phosphate buffered saline containing 0.1 % polysorbate 20 
PCL polycaprolactone 
PEG polyethylene glycol 
PGA polyglycolide 
PI propidium iodide 
PLA polylactide 
PLGA poly(lactic-co-glycolic acid) 
PVDF polyvinylidene fluoride 
rhBMP recombinant human bone morphogenetic protein 
rpm rounds per minute 
RT room temperature 
SDS sodium dodecylsulfate 
SDS-Page sodium dodecylsulfate polyacrylamide gel electrophoresis 
SEC size exclusion chromatography 
TCP tri-calcium-phosphate 
TGF transforming growth factor 
Tm melting temperature 
tmax time to maximum concentration at 
TRIS tris(hydroxyethyl)-aminomethane 
VEGF vascular endothelial growth factor 
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